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Synopsis  
Bone healing, regeneration, maintenance, and bone defect repair is dependent 
on the regenerative capacity of Osteoblasts.  Bone resorption, osteoporosis, peri 
implantitis and bone loss are caused by the activity of Osteoclasts.  It is the balance in 
activity between bone regeneration by Osteoblasts and bone resorption by Osteoclasts 
which determines if bone regeneration or bone loss occurs.  Osteoblast and Osteoclast 
cells respond to growth factors and bioactive inhibitors within the local environment, and 
the concentrations of these molecules may help determine if bone loss or bone 
regeneration occurs.  To develop new therapies which can promote bone regeneration 
and avoid bone resorption: I studied the effects of three growth factors: Spingosine-1-
Phosphate (S1P), Bone Morphogenic Protein-2 (BMP-2), and Growth Factor Beta 1 
(TGF-B1) and several bioactive inhibitors: FTY720, K02288, A83-01, M5939, 
Osteostatin, Sclerostin, Odanacatic, Carfilzomib, Phloretin, Decitabine, Amiloride, 
Osteoprotegerin, Tacrolimus, Cabozantinib, Cathepsin inhibitor, GM 6001 and 
Osteostatin.  To overcome the problem of the short lifespan of Osteoblasts and 
Osteoclasts:  I used a lenti-virus to immortalize the cells to increase their lifespan, and I 
created two novel cell lines for my research, which I have named “Immortalized 
Osteoblasts” and “Immortalized Osteoclasts.” My research design comprised of 54 
treatment groups and a total of 896 specimens.  Several interesting novel results were 
observed, as follows: 
First, I investigated and compared the migration responses of immortalized 
Osteoblast and Osteoclast cells in response to three growth factors and four bioactive 
inhibitors using a transwell cell migration assay.  I observed that S1P was the most 
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effective promoter of Osteoblast and Osteoclast migration, because S1P was able to 
increase cell migration by almost 3,000% and 1,000% respectively.  The most effective 
inhibitor of Osteoblast (94%) and Osteoclast (100%) migration was Sclerostin. 
Second, I investigated and compared the proliferation of immortalized Osteoblast 
and Osteoclast cells using a MTT spectrophotometer assay in response to growth 
factors and bioactive inhibitors.  I observed that Phloretin was the most effective 
promoter of Osteoblast proliferation (394%), and that Amiloride was the most effective 
promoter of Osteoclast proliferation (899%).  The most effective inhibitor of Osteoblast 
proliferation was GM6001 (-69%), and the most effective inhibitor of Osteoclast 
proliferation was Tacrolimus (-71%).  
Third, I investigated and compared the mineralization of bone by Osteoblasts 
using a spectrophotometer mineralization assay in response to growth factors and 
bioactive inhibitors.  I observed that S1P was the most effective promoter of Osteoblast 
mineralization (408%). 
Fourth, I investigated and compared the degradation of Collagen by Osteoclasts 
using a Mouse Tail Collagen Type-1 spectrophotometer degradation assay in response 
to growth factors and bioactive inhibitors.  I observed that FTY720 was the most 
effective compound at preventing collagen degradation (506%).  
Fifth, I compared the mean overall bioactive effects of many bioactive molecules 
on Osteoblasts and Osteoclasts, and discovered that the most bioactive was S1P.  The 
average effect of S1P in six assays was 734%. The least effective compound was 
GM6001.  The mean effect of GM6001 in six assays was -19%.   
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Sixth, I designed a hypothetical scaffold comprising of S1P, Phloretin, and 
FTY720, that could be developed to be implanted into bone defects and empty tooth 
sockets to promote bone regeneration, and to prevent osteonecrosis, osteoporosis, and 
peri implantitis.  Due to a lack of time and money, I was unable to investigate the 
effectiveness of my hypothetical scaffold, but it is my recommendation for future 
research in clinical trials to determine if it will benefit patients. 
 My sincere hope is that patients, the dental profession, and manufacturers of 
osteoregenerative materials, scaffolds and membranes will benefit from the ideas 
developed in my thesis.  I recognize that the treatment of bone defects, fractures, and 
infected bone can be difficult because of the long time it takes (months and years) to 
regenerate new replacement bone.  Clearly a new generation of bioactive bone repair 
materials, scaffolds and membranes could have the potential to increase the speed and 
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Glossary of statistical terms 
 
ANOVA         Analysis of variance, a statistical test that provides the probability of 
Whether or not there are any differences among two or more means of 
Several groups. 
 
Scheffe Test   This test is a multiple comparison post hoc ANOVA test to test the 
Probability that there are differences among the means of several groups. 
 
Chi Square    This test is non parametric statistical test used to determine if a 
distribution of observed frequencies differs from the theoretical expected frequencies. 
 
P value            The probability of obtaining a result as extreme as the one that was 
Actually observed from chance alone. The P value significance level used 








Products and materials in this research 
 
Name                                                     Supplier                                City, State 
 
Amphotericin B solution (Fungizone)    JRS Inc                        Woodland, CA 
 
Bleach solution                                      Clorox                                       Aokland, CA 
 
Collagen I Assay plates                        Corning                                     Lowell, MA 
 
Costar Transwell                               Corning Inc.                                  Corning, NY 
 
CollaPatch Wound Dressing              Zimmer Biomet                            Warsaw, IN 
 
Corning Osteo Assay plate                    Corning                                    Lowell, MA 
 
Cell culture differentiation medium         Gibco                                      Grand Island, NY 
 
Demineralized freeze-dried  
 
bone allograft (DFDBA)                     Miami Tissue Bank                      Miami, FL 
 
Dulbecco’s Modified Eagle Medium      Gibco                                       Grand Island, NY 
 
EDTA solution                                    Mediatech Inc.                            Manassas, VA 
 
Fetal Bovine Serum                               RMBIO                                    Missoula, MT 
 
Freeze-dried bone allograft (FDBA)    Miami Tissue Bank                    Miami, FL 
 
GM-CSF                                             Sigma Aldrich                             St. Louis, MO 
 
Human fetal osteoblasts (hFOB)       CRL-11372, ATCC                      Manassas, VA 
 
Lipofectamine LTX kit (A12621)  Life Technologies              Carlsbad, CA 
 
Lenti-hTert-GFP, Cat #: LG508           Biogenova                                 Rockville, MD 
 
MTT Cell Proliferation Assay Kit          Biotium                                      Hayward, CA 
 
MEM-Alpha culture media                     Gibco                                       Grand Island, NY 
 
Minimum Essential Medium-Alpha  
 26
         
A10490, MEM-Alpha,                             Gibco                                      Grand Island, NY 
 
Neutral-buffered formalin                   Fisher Scientific                           Nepean, ON 
 
Neutral red dye                                   J.T. Baker                                   Phillipsburg, NJ  
 
Osteo Bone Assay plates                      Corning                                    Lowell, MA 
 
Photoshop                                             Adobe                                      San Jose, CA 
 
Penicillin/streptomycin antibiotics           VWR                                       Suwanee GA 
 
Progenitor monocyte cell line              CRL-11372, ATCC                     Manassas, VA 
 
RANK ligand                                       Sigma Aldrich                             St. Louis, MO  
 
STATview software                             SAS Inc.                                     Gary, NC 
 
Spectrophotometer                             Genesys 20  
 
                                                           Thermo Fisher Scientific             Waltham, MA 
 
















1.1 Mechanism of bone mineralization and resorption  
Craniofacial bone healing following trauma or disease is a multifactorial process 
that requires activated osteoblast cells to mineralize bone. At the same time, 
osteoclasts continually resorb bone, however sometimes they resorb too much bone at 
the site of injury and disease. Both osteoblast and osteoclast cells are the progeny of 
mesenchymal stem cells located in bone marrow. The mechanism of bone 
mineralization and resorption is a process regulated by the interaction of bioactive 
molecules, osteoblast and osteoclast cells (1). 
  
1.2 Critical size defect  
Critical size defects can be defined as the smallest size of intraosseous wound 
that will not heal spontaneously. A bone defect larger than a critical size cannot 
regenerate without surgical intervention (2).  Larger bone defects above a specific injury 
size will require a surgery to be regenerated (3).  The major bone defects known as 
“critical-sized bone defects” are so called because they exceed the critical size where 
the bone can regenerate spontaneously by itself (4).   
 
1.3 Types of bone regeneration materials 
The most common treatment for critical-size bone defects requires the filling of 
the defect with a regeneration biomaterial. The physiology of bone mineralization of 
critical size defects was studied using biomaterials like for example autogenous bone 
graft, a freeze-dried bone allograft (FDBA) (5) or demineralized (DFDBA) from a 
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cadaver (6), or a synthetic bone alloplast implant material as a substitute for a bone 
graft (7). The effectiveness of bone regeneration biomaterials is controversial because 
of their variability to induce bone regeneration of the defect site. The selection of bone 
regeneration biomaterials can significantly affect the volume and quantity of bone 
formation. Generally, the operator will select bone regeneration biomaterials based on 
their training and experience to accomplish socket preservation, ridge augmentation 
and sinus augmentation. These biomaterials have different properties which an operator 
can use to accomplish optimal bone regeneration (8).  
 
1.3.1 Demineralized Freeze-Dried Bone Allograft (DFDBA) bone material 
Demineralized Freeze-Dried Bone Allograft (DFDBA) is widely used as a bone 
regeneration biomaterial for the treatment of periodontal and implant bone defects due 
to its osteoinductive ability. The demineralization process of the DFDBA exposes the 
Bone Morphogenetic Proteins 2 (BMP2) which will induce mesenchymal cells to 
differentiate into bone forming cells. The variability of DFDBA to regenerate bone within 
a critical sized defect can be due to in sufficient active quantities of BMP2. Some 
DFDBA batches are more bioactive than others depending on the age, gender and 
health of the donor. The particle size and sterilization methods could also inactivate the 






1.3.2 Synthetic Bone Alloplast biomaterial  
Synthetic Bone Alloplast (SBA) biomaterial can be used as a substitute to 
DFDBA bone. An ideal biomaterial needs to be compatible, resorbable and porous to 
allow rapid vascularization and mineralization.  The major types of SBA are: calcium 
phosphate, polymer scaffolds, collagen matrices, among others.  The properties of SBA 
biomaterial can influence bone regeneration.  Some SBA are inert which has minimal 
interaction with host tissue, some are bioactive that interacts with surrounding tissues 
and others are bioresorbable. SBA can be more advantageous compared to FDBA or 
DFDBA because it can avoid the need to obtain donor bone from a cadaver (11).  A 
limitation of SBA biomaterials is that they have not generally been very effective to 
regenerate bone in critical-sized defects (12). 
 
1.4 Bioactive mediators of bone regeneration   
A search of the scientific and clinical literature identified the three most important 
bioactive mediators of bone regeneration and osteoblast migration, proliferation, and 
mineralizing activity as: Sphingosine-1-phosphate (S1P) (13), Transforming Growth 
Factor Beta (TGF- β1) (14) and Bone Morphogenic Protein-2 (BMP-2) (15).  These 
three bioactive mediators have been extensively studied and have been found to 
regulate bone regeneration (16), osseointegration of implants (17), osteoblast activity 





1.4.1 Sphingosine-1-phosphate (S1P) and FTY720.   
Sphingosine-1-phosphate (S1P) is a blood borne bioactive lipid mediator (20).  
Sphingosine can be released from ceramides; which are known to have a regulatory 
function in apoptosis, through a process catalyzed by the enzyme ceramidase (21). The 
phosphorylation of sphingosine is catalyzed by sphingosine kinase, an enzyme 
ubiquitously found in the cytosol and endoplasmatic reticulum of various types of cells 
(22). S1P can be dephosphorylated to sphingosine by sphingosine phosphatases and 
can be irreversibly degraded by an enzyme, Sphingosine phosphatelyase (23). S1P is 
of importance in the entire human body, it is a major regulator of the migration 
(trafficking) and differentiation of immune cells from the vascular system into injured 
tissues or sites of infection or disease.  Poor vascularization is a main causative factor 
for post-operative complications following a massive bone allograft. To overcome this 
limitation, a novel polymer coating system with local delivery of FTY720; an agonist for 
S1P receptor, showed a superior host-graft integration and a better allograft 
vascularization. (24).  A search for S1P inhibitors in the scientific and clinical literature 
identified FTY720 also known as Fingolimod or Gilenya; as a potential agent to be 
investigated to inhibit osteoblast and osteoclast activity to S1P (25).  These have been 







1.4.2 Transforming Growth Factor Beta (TGF- β1) and A83-01  
Transforming Growth Factor Beta (TGF- β1) is released from the clot by platelets 
in a latent form and then becomes activated by a number of molecules; a furin-like 
enzyme which is simultaneously released by the platelets, involved in extra cellular 
matrix perturbations. TGF-β1 is abundant in bone matrix and is a potent cytokine for 
signaling injury and in controlling cell growth, chemotaxis, proliferation, and 
differentiation of progenitor cells into osteoblasts to accomplish the regeneration of bone 
(27).  TGF-β1 can be released from bone and also be synthesized by many cell types, 
including platelets leukocytes, osteoblasts and osteoclasts. TGF-β1 can coordinate 
bone resorption with subsequent bone formation by inducing the migration of bone 
marrow mesenchymal cells to bone resorptive sites and prevent fractures (28).  Almost 
all the cells which synthesize TGF-β1 have specific receptors for this peptide, which can 
create autologous signaling networks (29). TGF-β1 can inhibit bone resorption, by 
preventing osteoclast activation (30), and also be released during bone resorption which 
can activate osteoclasts (31).  Given the complex relationships between TGF-β1 and 
bone regeneration or resorption, there is a need to investigate the effects of TGF-β1 
and its inhibitors on osteoblast and osteoclast activity.  A search for TGF-β1 inhibitors in 
the scientific and clinical literature identified A83-01 as a potential agent (32) to be 
investigated to inhibit osteoblast and osteoclast activity. 
 
1.4.3 Bone Morphogenetic Proteins (BMPs) and K02288 
Bone Morphogenetic Proteins (BMPs) are a subgroup of TGF-β1 that are 
involved in various stages of bone healing and de novo bone formation.  BMPs bind to 
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type I and type II serine/threonine kinase receptors. BMP heteromeric receptor 
complexes activate intracellular proteins known as Smads (small ‘mothers against’ 
decapentaplegic) which translocate to the nucleus activate mineralizing genes (34).  
BMP signaling plays leading roles in embryonic developing, tissue remodeling and 
maintaining physiologic balance. It has been widely noticed that deranged BMP 
signaling contributes to developmental and postnatal diseases.   A search for BMP-2 
inhibitors in the scientific and clinical literature identified K02288 as a potential agent 
(35) to be investigated to inhibit osteoblast and osteoclast activity to BMP-2.  BMP 
inhibitors regulate local negative feedback mechanisms (36).  Some act extracellularly, 
preventing BMP binding to receptors, whereas others act intracellularly, inhibiting Smad 
downstream activation (37).  Overall, BMP inhibitors lead to down regulation of BMPs, 
inhibition of MSC differentiation to osteoblasts, and poor fracture healing (38). On the 
other hand, it has been demonstrated that the lack of BMP inhibitors in knockdown mice 
has an adverse effect on development of the musculoskeletal system especially that 
BMP plays a significant role in embryonic development, neural patterning, 
organogenesis, bone and cartilage formation. (39).  A search of the scientific and 
clinical literature has identified several osteoclast inhibitors with varying mechanisms of 







1.5 Osteoclast inhibitors  
The osteoclast inhibitors are described in the following paragraphs: 
 
1.5.1 Odanacatib  
Odanacatib (also known as MK-0822) is an investigational drug treatment for 
osteoporosis and bone metastasis. It was found to be useful in treatment of cancer-
induced osteolysis and skeletal tumor load. However, their chronic use in cancer and 
osteoporosis therapy may result in some side effects due to their accumulation in acidic 
organelles such as lysosomes. Thus, their use may be limited to treatment of life-
threatening conditions like bone metastasis (40).  Odanacatib is an inhibitor of cathepsin 
an enzyme involved in bone resorption (41).  A Phase 2 clinical trial of Odanacatib 
indicated that a 50 mg dose once weekly can inhibit bone resorption, increase bone 
mineral density, and increase bone formation (42).  The inhibitor effects of Odanacatib 
on osteoclasts and its effects on human osteoblasts have not previously been studied in 
vitro, further research is needed to define its therapeutic potential. 
 
1.5.2 Carfilzomib 
 Carfilzomib (also known as Kyprolis) is a selective proteasome inhibitor which is 
widely used to treat patients with multiple myeloma, tumors and other cancers. More 
than ten thousand multiple myeloma death cases have been issued in United States in 
2012. The introduction of bortezomib as anti-cancer therapeutic agent, including 
multiple myloma and mantel cell lymphoma, has resulted in further interest in 
proteasome as a target in the treatment of wide range of cancers (43).  Carfilzomib 
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irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome. Inhibition of 
proteasome-mediated proteolysis results in a build-up of polyubiquinated proteins, 
which may cause cell cycle arrest, apoptosis, and inhibition of tumor growth (44).  Little 
else is known about Carfilzomib, more research is needed to establish its ability to block 
osteoclast activity. 
 
1.5.3 Phloretin  
 Phloretin is a type of natural phenol called dihydrochalcone which can be found 
in apple tree leaves.  Phloretin can inhibit the active transport of glucose into cells.  An 
eight-week rodent study of Phloretin on bone loss in female mice displaying 
postmenopausal osteoporosis found that 10 mg/kg phloretin improved their bone 
density to OVX mice for 8 weeks improved such effects, compared to sham-operated 
mice (45, Lee et al 2014). Phloretin attenuated TRAP activity; histochemical marker for 
osteoclasts, and cellular expression of β3 integrin and carbonic anhydrase II augmented 
in femoral bone tissues of OVX mice (45). This study further examined that osteogenic 
activity of phloretin in RANKL-differentiated Raw 264.7 macrophages into mature 
osteoclasts (45). Phloretin at 1-20 μM stimulated Smac expression and capase-3 
activation concurrently with nuclear fragmentation of multi-nucleated osteoclasts, 
indicating that this compound promoted osteoclast apoptosis (46). Phloretin was 






 Decitabine can silence the transcription of a gene, preventing it from being 
expressed (48).  A potent a cytosine nucleoside analog that, once incorporated into 
DNA, inhibits further DNA methylation is known as Dacogen or 5-aza-2'-repression 
deoxycytidine) (49).  DNA methylation is important for maintenance of stable 
suppression of gene transcription in the course of differentiation and tumorigenesis.  
During osteoclastogenesis, changes in DNA methylation occurs in several genes, 
implicating important roles for DNA methylation in osteoclast activation (50).  Decitabine 
represses osteoclastogenesis through inhibition of RANK and NF-κB, presenting a 
novel strategy in treatment of diseases associated with increased osteoclast activity 
(50).  Decitabine is a drug for the treatment of myelodysplastic syndromes, a class of 
conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia 
(AML A clinical trial of Decitabine showed that it was effective in the treatment of 
myelodysplastic syndromes by reducing osteoclast and aberrant immune cell activity 
(51).  There is a need for research to study the direct in vitro effects of Decitabine on 
osteoclasts and osteoblasts. 
 
1.5.5 Amiloride 
 Amiloride is a potassium-sparing diuretic, first approved for use in 1967 (then 
known as MK 870), used in the management of hypertension and congestive heart 
failure.  Amiloride blocks Na+/H+ exchangers and can disrupt the endoplasmic 
reticulum and cytosolic Ca2+ homeostasis within target immune cells causing them to 
undergo apoptosis, also called programmed cell death (52).  Amiloride can also block 
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the osteoclasts from degrading bone by inhibiting the activity of vacuolar H+-ATPase 
(53).  The inhibition of H+-ATPase prevents osteoclasts from secreting protons which 
creates a local acidic microenvironment necessary for bone resorption (54).  Amiloride 
can also suppress other intracellular signaling molecules and membrane receptors, 
such as by blocking nuclear factor-κB and mitogen-activated protein kinase activity, this 
can inhibit osteoclastogenesis (55).  There is a need to investigate the direct effects of 
Amiloride on osteoclasts and osteoblasts, to determine if it preferentially can target 
osteoclast survival or reduce osteoclast resorption.   
 
1.5.6 Osteoprotegerin (OPG) 
Osteoprotegerin (OPG) is a glycoprotein which can prevent osteoclast 
differentiation from precursor cells (56).  OPG also known as osteoclastogenesis 
inhibitory factor (OCIF), or tumor necrosis factor receptor superfamily member 11B 
(TNFRSF11B) (57), is a decoy protein for the receptor activator of nuclear factor kappa 
B ligand (RANKL) in humans. OPG is produced by different tissues including 
cardiovascular system, lung, kidney, intestine, bone and immune cells. The expression 
of this protein is upregulated by various cytokines like: TNF-α, IL-18, (TGF)- β, BMP and 
some steroid hormones. RANKL is produced by osteoblasts and its production is 
modulated by different cytokines such as: IL-1, IL-6, IL-11, TNF- α, glucocorticoid and 
PTH. RANKL stimulates its definitive receptor RANK; which is found on mature 
osteoclast surface, and initiates a cascade of signaling pathways that enhances bone 
resorption and bone loss. OPG acts as a soluble inhibitor that prevent excessive bone 
resorption by binding to RANKL and preventing it from subsequent stimulation with its 
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receptor, RANK (58).  The differential effects of OPG on osteoblasts versus osteoclasts 




 Tacrolimus (also known as FK-506, Fujimycin, Prograf, Advagraf, and Protopic) 
is an immunosuppressive macrolide calcineurin inhibitor first approved by the FDA in 
1994 for use after allogeneic organ transplants to reduce the activity of the patient's 
immune system and to lower the risk of organ rejection (59).  Tacrolimus was first 
produced by S. tsukubaensis, which is a microorganism found in soil (60).  Tacrolimus 
is an osteoclast inhibitor which explains its immunosuppressive effects in patients (61).  
However, it is not clear if Tacrolimus can target osteoclasts and leave osteoblasts 
unaffected by its inhibitory effects, more research is needed to ensure that Tacrolimus 
specifically targets osteoclasts. 
 
1.5.8 Cabozantinib 
Cabozantinib (also known as Cometriq, XL184 and 849217-68-1) can inhibit 
the tyrosine kinases c-Met and VEGFR2; which plays an essential role in the 
progression of metastasis, which reduces tumor growth, metastasis, and angiogenesis. 
It can effectually inhibit tumor growth in murine models of prostate cancer; that have 
osteoblastic components, mainly due to its capacity to target both the tumor cells 
themselves and microenvironment cells (62).  Cabozantinib was first approved by the 
FDA in 2012 for the treatment of medullary thyroid cancer (63).  Cabozantinib can inhibit 
 38
osteoclast activity (64) but it remains unclear if it can be effective for maintaining 
osteoclast survival or reducing osteoclast resorption.   
 
1.5.9 Reveromycin   
Osteoporosis and other disorders associated with excessive bone loss are 
directly caused by the activity of osteoclasts (65).  Reveromycin, is a small natural 
product with three carboxylic groups in its structure (66).  Reveromycin can induce 
apoptosis specifically in osteoclasts, but not in osteoclast progenitors, nonfunctional 
osteoclasts, or osteoblasts (67).  The osteoclast apoptosis induced by Reveromycin is 
not accompanied by necrosis (68).  There is a need to further investigate the direct 
effects of Reveromycin on osteoclast migration, proliferation and collagen degradation. 
 
1.5.10 Cathepsin B 
Cathepsin B is a ubiquitously expressed cysteine involved in remodeling of the 
extracellular matrix needed for molecular signaling which mediates physiological 
processes such as wound healing, cell migration, mineralization and resorption. In 
addition to its physiological roles, cathepsin B is important in many pathological 
processes, such as inflammation, parasite infection and cancer, where it is highly up-
regulated. Cathepsin B inhibitor is a potent and selective irreversible cell permeable 
cathepsin B inhibitor (69). Cathepsin inhibitors can inhibit osteoclastogenesis via 
suppression of the NFATc1 and c-FOS signaling pathways in isolated mouse 
osteoclasts (70).  There is a need to further investigate the direct effects of Cathepsin B 




Osteostatin is a carboxyl-terminal peptide sequence of 107-111 derived from 
parathyroid hormone related protein (PTHrP). Osteostatin induces rapid cellular 
reduction of both human and rat cultured osteoclasts, which was morphologically 
distinct from that produced by calcitonin, a hormone that is produced by parafollicular 
cells of the thyroid and reduces the effect of osteoclast activity in bone (71).   
Osteostatin is a potent inhibitor of osteoclastic bone resorption (72) and counteracts the 
stimulatory effects of PTHrP (73) and potentially other proteins on osteoclasts.   
Osteostatin can inhibit osteoclast resorption (71) but it remains unclear if it can be 
effective for maintaining osteoclast survival or reducing osteoclast survival.   
 
1.6 Bone physiology 
Bone is a dynamic tissue that contains four major cell types: osteoblasts, 
osteoclasts, osteocytes, and osteoprogenitor (or osteogenic) cells.  The most important 
cell type is the osteoblast which constantly mineralizes new bone (74).  The osteoblasts 
produce and secrete collagen and other bone matrix proteins and they transport 
minerals into the bone matrix (75) to form a strong mineral-dense skeletal bone 
structure (76).  As the secreted matrix surrounding the osteoblast calcifies, the 
osteoblast becomes trapped within it. As a result, it changes in structure, becoming an 
osteocyte, the primary cell of mature bone and the most common type of bone cell.  
Osteogenesis describes the process of osteoblast formation from progenitor cells called 
mesenchymal stem cells located in the periosteum and bone marrow (77).  The in vivo 
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proliferation and differentiation of progenitor cells into osteoblasts is regulated by growth 
factors, mainly Bone Morphogenetic Proteins (BMPs) (78), and Transforming Growth 
Factor beta (TGF-β) (79), together with some other growth factors and hormones.  
 
1.7 Bone and joint mineralization disorders 
 Bone mass is regulated by feedback from osteocytes; which are osteoblasts 
buried in the bone matrix (80), physical activity (81), the presence of growth factors and 
hormones (82), and autoimmune disease characterized by chronic inflammation and 
bone destruction.  The most common autoimmune disease is osteoarthritis (OA), it can 
cause constant joint pain, suffering, reduced limb function, loss of mobility, and loss of 
quality of life for 27 million Americans (83).  Americans have a 46% and 25% lifetime 
risk of developing OA in their knee and hip, particularly as they increase in age (84).  A 
third of elderly American women suffer from OA, which is a progressive loss of bone 
mineral which increases their risk of bone fracture (85).  Bone and joint mineralization 
disorders become increasingly common in middle-age and elderly people, but it is not 
accurate to claim that the joints and bone have “worn out” (85).  This is because in 
healthy people, the deposition of bone by osteoblasts is matched by the resorption of 
bone by osteoclasts (86).  Whenever there is an abnormal increase in bone resorption it 
is because the osteoclasts have become more active and resorbed bone and 
surrounding soft tissues (87). Osteoclasts are bone-resorbing giant polykaryon cells that 
have differentiated from mononuclear macrophage/monocyte-lineage haematopoietic 
precursors (88).  The osteoclast progenitor cells migrate and attach to the bone surface, 
where growth factors can promote cell fusion, where the cells form giant osteoclast cells 
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which resorb bone (89).  If the activity of osteoclasts can be blocked by any of the 
previously described inhibitors, it may prevent bone resorption (90).    
 
1.8 Cell immortalization  
Research using cell cultures of osteoblasts and osteoclasts are rare, because 
they have a half-life of only 4 days (91).  In this study, the short-life span of the 
osteoblasts and osteoclasts will be addressed by transfecting the cells with a 
recombinant lentivirus (Lenti-hTert-GFP, Cat #: LG508, Biogenova, Rockville, MD) (92) 
to create immortalized osteoblast and osteoclast cell lines for experimentation.  
Although the term “immortalized” is used, this does not mean the cells will last forever, 
but it is expected that their half-life will increase dramatically to allow us to grow enough 
osteoblasts and osteoclasts for our experiments. 
 
1.9 Cell migration   
Cell migration is needed for homeostatic tissue maintenance and the 
regeneration of injured organs and tissues (93).  Cells must migrate to sites where they 
are required to function, otherwise the regeneration and development of functional 
organs and tissues would be impossible (94), included bone mineralization.  
Conversely, deregulated cell migration can result in the development of pathologies and 
autoimmune dysfunctions (95).  A search of the literature has identified no previous 
studies which have investigated the in vitro migration of osteoblasts and osteoclasts in 
response to growth factors with or without inhibitors.  There was a need to investigate 
what effects the addition of growth factors: S1P, TGF-1, and BMP-2 can have on the 
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migration of osteoblasts and osteoclasts in comparison to negative controls, which 
contain no growth factors.  There was also a need to investigate the effectiveness of the 
inhibitors: FTY720, K02288, A83-01, and Sclerostin to block the migration of 
osteoblasts and osteoclasts to S1P, TGF- β1, and BMP-2.   
 
1.10 Cell proliferation 
Cell proliferation is the increase in cell numbers as a result of cell growth and 
division, and is defined by the balance between cell divisions and cell loss through cell 
death (96).  Several bioactive molecules can increase osteoblast cell proliferation, such 
as TGF- β1, and BMP-2 (97) as well as S1P (98), but there have been no precise 
comparisons of TGF- β1, BMP-2, and S1P on osteoblast proliferation, so it is not known 
which of these growth factors is the most potent to stimulate osteoblast proliferation to 
increase the rate of ostegenesis and bone formation.  Unfortunately, the use of growth 
factors to promote osteoblast proliferation, may also promote osteoclast proliferation 
(98) and osteoclastogenesis which could increase the rate of bone degradation (99).  
This explains the need to investigate and compare the effects of TGF- β1, BMP-2, and 
S1P on osteoblast proliferation as well as osteoclast proliferation to ensure that the 
effects of the growth factors are primarily on osteoblasts and not osteoclasts.  Some 
potential osteoclast inhibitors are:M5939, Osteostatin, Odanacatic, Carfilzomib, 
Phloretin, Decitabine, Amiloride, Osteoprotegerin, Tacrolimus, Cabozantinib, Cathepsin 
inhibitor, GM 6001 and Osteostatin.  These osteoclast inhibitors have the therapeutic 
potential to block osteoclast proliferation, but it is not clear if they also block the activity 
of osteoblasts, hence the need to investigate and compare the effects of these inhibitors 
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on osteoblasts.  We are investigating and comparing the effectiveness of the inhibitors 
to block the bone resorbing activity of osteoclasts because these are the only somatic 
cell type capable of resorbing bone matrices (100). 
 
1.11 Bone mineralization 
Bone mineralization is a complex process which is not fully understood (101), the 
best understood aspect is the mineralizing role of the osteoblast (102), hence the need 
to investigate the effects of TGF- β1, BMP-2, and S1P on the mineralization of 
osteoblasts. Bioactive molecules including TGF- β1 (103), BMP-2 (104), but not S1P 
(105) can promote increased osteoblast mineralization, but the effects of osteoclast 
inhibitors (M5939, Osteostatin, Odanacatic, Carfilzomib, Phloretin, Decitabine, 
Amiloride, Osteoprotegerin, Tacrolimus, Cabozantinib, Cathepsin inhibitor, GM 6001 
and Osteostatin) have not been investigated for their effects on mineralization. 
 
1.12 Collagen degradation within bone  
Bone is a composite material in which collagen fibrils synthesized and secreted 
by osteoblasts form a scaffold for a highly organized arrangement of uniaxially oriented 
apatite crystals (106).  Collagen is derived from “kola”, the Greek word for glue, and 
“gen” denoting producing.  Collagen-1 is the major structural protein within bone and is 
the most abundant protein (25-35%) within the human body.  Osteoclasts dissolve bone 
mineral by acid secretion and the secretion of specialized proteinases that degrade the 
organic matrix, mainly composed of collagen-1 (107).  The site of bone dissolution is a 
high-calcium environment; removal of degradation products by transcytosis of 
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membrane vesicles allows the osteoclast to maintain a normal intracellular calcium 
(107).  At the molecular level it is necessary to investigate and compare the collagen 
degradation activity of osteoclasts in response to bioactive molecules (S1P, TGF-1, 
BMP-2) bioactive inhibitors (FTY720, K02288, A83-01, and Sclerostin) and osteoclast 
inhibitors (M5939, Osteostatin, Odanacatic, Carfilzomib, Phloretin, Decitabine, 
Amiloride, Osteoprotegerin, Tacrolimus, Cabozantinib, Cathepsin inhibitor, GM 6001 
and Osteostatin). 
 
1.13 Objectives of my research  
The objective of my research was to develop more effective bone regenerative 
treatment. This required that I investigate the use of bioactive molecules to stimulate the 
migration, proliferation, and mineralizing activity of osteoblasts and osteoclasts as well 
as the inhibitors. I searched the scientific literature and have selected the three most 
common growth factors to be investigated, there are: Sphingosine-1-phosphate (S1P), 
Transforming Growth Factor Beta (TGF- β1), and Bone morphogenetic protein-2 (BMP-
2).  These were investigated with and without four bioactive inhibitors (FTY720, K02288, 
A83-01, and Sclerostin) and eleven osteoclast inhibitors (M5939, Osteostatin, 
Odanacatic, Carfilzomib, Phloretin, Decitabine, Amiloride, Osteoprotegerin, Tacrolimus, 
Cabozantinib, Cathepsin inhibitor, GM 6001 and Osteostatin). Little or no attention has 
been focused on combining drugs to stimulate the activity of osteoblasts to regenerate 
bone and at the same time using inhibitors which block osteoclasts from resorbing 
bone, within a novel bone regeneration material.  Ideally a bone defect repair and bone 
augmentation material would be a biodegradable synthetic scaffold which avoids the 
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need for harvesting donor bone and which contains drugs to predictably promote bone 
regeneration by stimulating osteoblasts and inhibiting osteoclasts. Traditional bone 
defect and bone augmentation materials are widely used, but it is recognized that they 
do not always give predictable bone regeneration results. 
My investigation of osteoblast and osteoclast migration, proliferation and 
mineralization responses to bioactive molecules (S1P, TGF- β1, BMP-2) bioactive 
inhibitors (FTY720, K02288, A83-01, and Sclerostin) and osteoclast inhibitors ( M5939, 
Osteostatin, Odanacatic, Carfilzomib, Phloretin, Decitabine, Amiloride, Osteoprotegerin, 
Tacrolimus, Cabozantinib, Cathepsin inhibitor, GM 6001 and Osteostatin) could yield 
the information needed to create new bone regeneration and bone augmentation 
scaffolds.  My central hypothesis was that once the promoters of osteoblast activity and 
inhibitors of osteoclasts have been identified, it will allow bone regeneration scaffolds to 
be developed using combinations of the promoters and inhibitors to guide bone 
regeneration.  
A summary of the activity of these bioactive molecules (S1P, TGF- β1, BMP-2), 
bioactive inhibitors (FTY720, K02288, A83-01, and Sclerostin) and osteoclast inhibitors 
(Odanacatic, Carfilzomib, Phloretin, Decitabine, Amiloride, Osteoprotegerin, Tacrolimus, 
Cabozantinib, Reveromycin C, Cathepsin B inhibitor, and Osteostatin) is shown in 








Figure 1.  Competitive bone regeneration and resorption between osteoblasts and 
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by osteoblasts 
Bone defect resorption 
by osteoclasts 
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2. MATERIALS AND METHODS  
2.1 Regulatory approval  
 The osteoblast and osteoclast cell cultures did not require an IRB review or 
approval, because they did not meet the federal or NSU institutional standards to be 
regarded as human subjects research.  No animals were used in this study, therefore it 
did not require an IACUC review and approval. 
 
2.2 Calculation of sample size  
Prior to the commencement of this research the sample effect size and alpha 
were calculated as follows:  
Effect size used the Cohen’s d at 4.61 and power = 0.80 (Two-Tailed Test).  
This study will use a total of 54 different treatment groups, each containing a minimum 
of 5 samples, giving a total of 896 samples.  This sample experimental design was 
similar to studies by previous NSU postgraduate residents (108,109).  This experimental 
design was used because it is likely to provide an effective balance between the costs 
and time needed to complete the study with the likelihood of observing significance 
differences.  The effect size in this study was sufficient to obtain a high power value and 
to detect the real effects of drugs on the migration, proliferation and mineralization of 
osteoblasts and osteoclasts. 
Alpha which related to the P value was set at the P < 0.05 significance level in 
this study (108,109).   
There are two main types of statistical errors, called Type I and Type II errors.  
A type I error involves the rejection of a null hypothesis that is actually true.  Rejecting 
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the null hypothesis when it is in fact true is called a Type I error.  Type I errors are 
equivalent to false positives (110).  A type I error might lead us to conclude that the 
drugs have effects on the migration, proliferation and mineralization of osteoblasts and 
osteoclasts. But if the null hypothesis was true, then in reality the drugs might have no 
effects on the migration, proliferation and mineralization of osteoblasts and osteoclasts.  
In order to avoid obtaining a false positive result, we repeated each of the treatments at 
least 5 times and analyze the trends within the data by grouping the effects of the drugs 
according to their effects on osteoblasts and osteoclasts. 
If the null hypothesis was accepted in this study, then our claim is that the drugs, 
did not have significant effects on the migration, proliferation and mineralization of 
osteoblasts and osteoclasts.  An error can occur when I did not reject a null hypothesis 
that is false. This sort of error is called a Type II error.  Type II errors are equivalent to 
false negatives. The probability of a type II error is given by the Greek letter beta (β). 
This number is related to the power or sensitivity of the hypothesis test, denoted by 1 – 
beta.  Typically, when I try to decrease the probability one type of error, the probability 
for the other type increases.  Thus, I designed a plan that conforms to previous studies 
(108,109) so that the probability of making statistical errors is within acceptable limits.  
Similar to our protection against a Type I error, I have analyzed the data from the 
migration, proliferation and mineralization groups up to 896 samples, in order to 
minimize the possibility of making any false positive or false negative results (Type I or 
Type II error) in this study. 
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2.3 Osteoblasts  
 An existing population of human fetal osteoblasts (hFOB 1.19, CRL-11372, 
ATCC, Manassas, VA) was used in this study.  These osteoblasts have been used in 
several previous studies to investigate the effects of bioactive molecules on their 
migration, proliferation and mineralization (111,112).    
 
2.4 Osteoclasts 
There is no pre-existing human osteoclast cell line that can be supplied from a 
vendor for this study.  The osteoclasts were created from a mouse progenitor monocyte 
cell line (RAW-264.7-LTX, ATCC, Manassas, VA) (113).  To differentiate the monocyte 
cells into osteoclasts, they were suspended in cell culture differentiation medium (Gibco, 
Grand Island, NY) supplemented with 10% Fetal Bovine Serum (FBS, RMBIO, 
Missoula, MT), 1% Pen/Strep (VWR, Suwanee GA), 50 ng/mL of RANK ligand (Sigma 
Aldrich, St. Louis, MO), GM-CSF (50 ng/ml) (Sigma Aldrich) and at a concentration of 
50,000 cells/mL.  The osteoclast progenitor cells were suspended in media at a volume 
of 100 µL, and concentration of approximately 5,000 cells per well, into a 96 well 
Corning Osteo Assay plate (Corning, Lowell, MA) to start the process for osteoclast 
differentiation.  Some negative control wells received the differentiation medium without 
cells.  The cells were placed inside an incubator at a temperature of 37°C and a 
humidified atmosphere of 5% CO2.  After 7 days, the cells adhering to the base of the 




2.5 Cell culture of osteoblasts and osteoclasts 
These osteoblast and osteoclast cells were cultured separately in Minimum 
Essential Medium-Alpha (A10490, MEM-Alpha, Gibco, Grand Island, NY) supplemented 
with 2 mM L-glutamine (Gibco), 10% FBS (RMBIO), and 1% concentration of 
penicillin/streptomycin antibiotics (VWR, Suwanee GA) and Amphotericin B solution 
(Fungizone, JRS Inc, Woodland, CA) collectively known as “culture media.”  The cells 
were submerged in culture media and were maintained within an incubator at 37ºC in a 
humidified atmosphere of 5% CO2.  The used culture media was removed and was 
replenished with fresh media every second day.  The confluent osteoblasts and 
osteoclasts (>85%) were collected by trypsinization (0.2% trypsin/EDTA).    
 
2.6 Assessment of the effectiveness of osteoclastogenesis 
The effectiveness of the procedure to differentiate the monocyte cells (RAW-
264.7-LTX) into osteoclasts (113) was evaluated by suspending them in MEM-Alpha 
culture media (Gibco) in 96 well Osteo Bone Assay plates (Corning) and 96 well 
Collagen I Assay plates (Corning).  After 7 days the culture media was aspirated with 
6.1% bleach solution (Clorox, Oakland, CA) for 5 minutes at laboratory temperature. 
The 96 well plates were washed with saline and dried for 5 hours.  The ability of the 
osteoclasts to degrade the Osteo coating on the plates was viewed at 100x 
magnification using a microscope.  The area of degraded osteo coating was measured 




2.7 Staining to identify fully differentiated osteoclasts 
The effectiveness of osteoclast differentiation can be evaluated using a telomere 
repeat amplification protocol (TRAP) (113).  My research plan was to perform a TRAP 
assay, but due to time and cost constraints, this was not completed. I recommend that 
future study perform a TRAP analysis of the osteoclast differentiation. 
 
2.8 Immortalization of osteoclasts and osteoblasts 
The osteoclast and osteoblast cells were harvested by releasing them from 
attachment to the plastic culture flasks using 0.25% trypsinization/2.21mM EDTA 
solution (Mediatech Inc., Manassas, VA).  The cells were centrifuged at 3,000 rpm for 5 
minutes and the waste supernatant media will be discarded.  The cells were plated in 
fresh culture media into the wells of a 48-well plate.  The cells were plated at a 
concentration of 6.2 x 104 cells per well in 0.5ml of complete Dulbecco’s Modified Eagle 
Medium (DMEM) cell culture media (Gibco) containing 2 mM L-glutamine, high glucose 
10% fetal calf serum, and a 1% concentration of penicillin/streptomycin antibiotics and a 
1% concentration of Amphotericin B solution (Fungizone, JRS Inc, Woodland, CA).  The 
cells were maintained in an incubator at 37ºC in a humidified atmosphere of 5% Carbon 
dioxide.  After 24 hours of cell culture had elapsed, the culture media was replaced with 
fresh cell culture media (Gibco) without fetal calf serum or antibiotics, because they 
interfere with transfection.  In each of the wells containing osteoclasts, 0.3 micrograms 
of a recombinant lentivirus (Lenti-hTert-GFP, Cat #: LG508, Biogenova, Rockville, MD) 
(42) was added with 0.375 microliters of Mix PLUS reagent and 1 microliter of LTX 
reagent both supplied in a Lipofectamine LTX kit (A12621, Life Technologies, Carlsbad, 
 52
CA) after it was mixed for 45 minutes at room temperature (37).  The lentivirus and 
lipofectamine reagents were incubated with the osteoclasts for 24 hours.  The 
effectiveness of the lentiviral infection was visualized using their fluorescence under a 
fluorescent microscope at 250x magnification.  The small numbers of non-infected and 
non-immortalized osteoclasts died off after a few days, leaving the lenti-virus infected 
and immortalized osteoclast or osteoblast cell line to continue growing.  Thus, 
accomplishing the goal of creating immortalized osteoclast and osteoblast cell lines for 
experimentation.  The effectiveness of the immortalization of the osteoclast and 
osteoblast cells were measured by growing them for 14 days prior to experimentation.  
At this time period, all the non-immortalized cells died off and the immortalized cells 
were still being growing. 
 
2.9 Migration of osteoblasts and osteoclasts in response to bioactive molecules 
and inhibitors. 
The osteoblasts and osteoclasts migration studies were performed separately to 
avoid confounding the results.  The osteoblasts or osteoclasts (cells) (3 x 106 cells/ml) 
were aliquoted within 100 µl of serum-free and growth factor-free culture media into the 
upper compartment of a 6 mm diameter migration chamber (Costar Transwell, Corning 
Inc., Corning, NY) which will be pre-warmed to 37oC.  The upper migration chamber had 
a base comprising of a polycarbonate filter containing 8 mm pores.  The cells were 
allowed to adhere to the filters for 2 hours at 37oC in a moist environment and 5% CO2 
atmosphere.  After cell adherence, the upper migration chambers were placed into 
lower chambers containing growth factors in the serum-free and growth factor-free 
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culture media (114).  The target growth factors and bioactive inhibitors (shown in Table 
1) were all tested at a concentration of (10 ng/ml), in accordance with a previous study 
(114), they were placed in the lower migration chambers.  FBS was added to the culture 
media in the lower migration chambers at a concentration of 10% v/v.  These solutions 
were prepared fresh immediately prior to experimentation to prevent gradient formation.  
In the control group (none) no growth factors were added.  The cells were incubated for 
4 hours. 
 
Table 1.  Migration of osteoblasts and osteoclasts in response  
to bioactive molecules and inhibitors 













None None n =5 




None None n =5 




S1P None n =5 




S1P None n =5 
5 Osteoblast responses 










6 Osteoclast responses 














TFG-β1 None  n =5 




TFG-β1 None  n =5 
9 Osteoblast responses 




TFG-β1 A83-01 n =5 
10 Osteoclast responses Osteo- TFG-1 A83-01 n =5 
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After migration, the upper chamber containing the filter was removed, and the 
cells were fixed with 10% neutral-buffered formalin (Fisher Scientific, Nepean, ON) for 
10 minutes.  The non-migrating cells attached to the upper side of the filter were 
carefully removed with a cotton swab, and the number of migrating cells attached to the 
lower side of the filter were stained with hematoxylin for 60 seconds.  The numbers of 
migrating cells attached to the filters were counted per microscope field at x200 
magnification using checker-board analysis (115) and a blind coded specimen 
technique for each of the different treatment protocols.  Each of the individual treatment 
protocols for each of the bioactive molecules and inhibitors, FBS, and negative control 
(no growth factor) were replicated x5 times (Table 1).  The numbers of attached cells 
were counted and analyzed using one-way analysis of variance (ANOVA) statistical 
to TFG-β1 inhibited by 
A83-01 
clasts 




BMP-2 None  n =5 




BMP-2 None  n =5 
13 Osteoblast responses 




BMP-2 K02288 n =5 
14 Osteoclast responses 




BMP-2 K02288  
n =5 
15 Osteoblast responses 




BMP-2 Sclerostin n =5 
16 Osteoclast responses 




BMP-2 Sclerostin n =5 
Total number of specimens = 80 
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tests.  The raw data were evaluated using STATview software, (SAS Inc, Gary, NC) at a 
confidence level of 95%.  
 
2.10 Proliferation of osteoblasts and osteoclasts in response to bioactive 
molecules and inhibitors 
The proliferation of osteoblasts and osteoclasts shown in Table 2 was measured 
by collecting the culture media and analyzing cell proliferation using a MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT Cell Proliferation Assay Kit, 
Biotium, Hayward, CA).  The MTT assay used a spectrophotometer (Genesys 20, 
Thermo Fisher Scientific, Waltham, MA) to measure the MTT absorbance reaction at 
562nm as a measure of osteoblast or osteoclast viability (116).  The proliferation of the 
osteoblasts and osteoclasts was expressed as a percentage of the positive controls 
(100%) and also a ratio of the negative control (0%). 
Table 2.  Proliferation, mineralization, and degradation activities of osteoblasts and osteoclasts 
in response  
to bioactive molecules and inhibitors 






















None None n =8 n =8  




None None n =8  n =8 
19 Osteoblast 
responses to S1P 
Osteo-
blasts 
S1P None n =8 n =8  
20 Osteoclast 
responses to S1P 
Osteo-
clasts 












None FTY720 n =8  n =8 










TFG-β1 None  n =8  n =8 
25 Osteoblast 
responses to A83-01 
Osteo-
blasts 
None A83-01 n =8 n =8  
26 Osteoclast 
responses to A83-01 
Osteo-
clasts 
None A83-01 n =8  n =8 
27 Osteoblast 
responses to BMP-2 
Osteo-
blasts 
BMP-2 None  n =8 n =8  
28 Osteoclast 
responses to BMP-2 
Osteo-
clasts 
BMP-2 None  n =8  n =8 
29 Osteoblast 
















None Sclerostin or 
M5939 






None Sclerostin or 
M5939 








































































2.11 Mineralization of osteoblasts in response to bioactive molecules and 
inhibitors 
Confluent osteoblasts were incubated in cell culture medium containing 10% 
FBS, 50 g/ml ascorbic acid, and 50 g/ml -glycerophosphate. The cells were treated with 
bioactive molecules or bioactive inhibitors summarized in Table 2 for up to 30 days.  
Mineralization of cell cultures was evaluated by alizarin red staining (117) and von 
Kossa’s staining (118). Quantification of Alizarin red staining was also performed, 
following the extraction procedure described by Gregory et al (117).  The end points of 








































































None Osteostatin n =8  n =8 
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the test groups in comparison to the controls (Table 2), by photographing them, and 
using Photoshop (Adobe, San Jose, CA) software to determine the greyscale dark-light 
intensity of the staining as a percentage of the controls, and then using this analysis to 
rank the bioactive molecules and inhibitors from most to least. 
 
2.12 Collagen degradation by osteoclasts in response to bioactive molecules and 
inhibitors 
Confluent osteoclasts were incubated in cell culture medium containing 10% 
FBS, 50 g/ml ascorbic acid, and 50 g/ml –glycerophosphate and plated on surfaces of 
rat tail type-1 collagen (118).  The cells were treated with bioactive molecules or 
bioactive inhibitors summarized in Table 2 for up to 30 days.  The ability of the 
osteoclasts to degrade the collagen was measured by a collagen degradation assay 
(118). The ability of the osteoclasts to degrade the collagen and bone was assessed 
using a light microscope at X200 magnification.  The images were photographed and 
the percentage of degradation where collagen and bone has been degraded appeared 
clear. Photoshop (Adobe) software was used to analyze what percentage of collagen 
and bone has been resorbed comparing the greyscale dark-light intensity for each of the 
treatment groups (Table 2).   
 
2.13 Future research of the effect of freeze-dried bone allographs on osteoblasts 
and osteoclasts 
I did plan to investigate the effect of freeze-dried bone allographs on osteoblasts 
and osteoclasts, but this was not done due to a lack of time.  My suggestion for future 
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research is that another researcher perform the following protocol: Sterile Freeze-dried 
bone allograft (FDBA, Miami Tissue Bank, Miami, FL), Demineralized freeze-dried bone 
allograft (DFDBA, Miami Tissue Bank), and Synthetic bone alloplast (Bio-Oss, Geistlich 
Pharma N.A., Princeton, NJ) will be incubated in DMEM at 37ºC for 30 minutes before 
application of the cells to equalize culture conditions between the scaffolds and cells.  
Osteoblasts and osteoclasts will be grown to confluence and harvested as previously 
described.  The cells will be added to the FDBA, DFDBA, and Bio-Oss as fresh aliquots 
(109) summarized in (Table 3).  During culture, 0.0016 % neutral red dye (J.T. Baker, 
Phillipsburg, N.J.) will be added as a cell viability marker to the DMEM in order to stain 
the vital cells dark red (109).  The scaffolds and cell cultures will be incubated at 37oC in 
a 5% CO2 atmosphere for seven days.   
 
Table 3.  Suggested comparison of novel synthetic biodegrable scaffolds with  freeze-dried 
bone allografts,  demineralized freeze-dried bone allograft, and  synthetic bone alloplast for 
the de novo mineralization of bone. 










Phase 5 scaffolds 
seeded with 
Osteoblasts 
55 Freeze-dried bone 
allograft 
FDBA Miami 
Tissue Bank,  
Miami, FL. 
Not done Not done 
56 Demineralized freeze-
dried bone allograft 
DFDBA Miami 
Tissue Bank,  
Miami, FL. 
Not done Not done 





Not done Not done 
58 Negative control scaffold 









2.14 Future creation of candidate scaffolds for bone regeneration 
I did plan to investigate the effect of freeze-dried bone allographs on osteoblasts 
and osteoclasts, but this was not done due to a lack of time.  My suggestion for future 
research is that another researcher perform the following protocol: Sterile biodegradable 
collagen scaffolds (CollaPatch Wound Dressing, Zimmer Biomet, Warsaw, IN) will be  
incubated in DMEM at 37ºC for 30 minutes before application of the cells to equalize 
culture conditions between the scaffolds and cells.  Osteoblasts and osteoclasts will be 
factors, inhibitors or 
drugs 
Dressing Warsaw, IN. 
59 Negative control scaffold 
without any growth 











60 Novel synthetic 
biodegrable scaffold 
containing the most 
potent osteoblast 
minerlization promoter 










Not done Not done 
61 Novel synthetic 
biodegrable scaffold 
containing the most 
potent osteoblast 
minerlization promoter 
and most potent 
osteoclast inhibitor  















62 Novel synthetic 
biodegrable scaffold 
containing the most 
potent osteoclast 
















Total number of specimens = 70  
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grown to confluence and harvested as previously described.  The cells will be added to 
each scaffold as fresh aliquots (109). During cell culture we will add the most potent 
osteoblast mineralization promoter identified in the previous stage of this study to one 
group of scaffolds seeded with osteoblasts and osteoclasts (Group 60, Table 3).  During 
cell culture we will add the most potent osteoblast mineralization promoter and most 
potent osteoclast inhibitor identified in the previous stage of this study to one group of 
scaffolds seeded with osteoblasts and osteoclasts (Group 61, Table 3).  During cell 
culture we will add the most potent osteoclast inhibitor identified in the previous stage of 
this study to one group of scaffolds seeded with osteoblasts and osteoclasts (Group 62, 
Table 3).  As a control, scaffolds will be seeded with osteoblasts or osteoclasts without 
any growth factors, inhibitors, or drugs (Group 58, Table 3).  As another control, 
scaffolds will not have any cells added, and will not contain any growth factors, 
inhibitors, or drugs (Group 59, Table 3).  During culture, 0.0016 % neutral red dye (J.T. 
Baker, Phillipsburg, N.J.) will be added as a cell viability marker to the DMEM in order to 
stain the vital cells dark red (109).  The scaffolds and cell cultures will be incubated at 
37oC in a 5% CO2 atmosphere for seven days.   
 
2.15 Biohazards 
The drugs, bioactive molecules, inhibitors, cells, culture flasks, plastics, pipettes, 
flammable chemicals and all plastics that came into contact with cells were disposed of 
according to NSU standard OSHA protocols for handling potentially bio-hazardous 
waste.  During cell culture and scaffold culture, a sterile handling technique was used, 
to prevent contamination.  At the end of experimentation, all the disposable items were 
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placed in biohazard bags.  Cells were stored in freezers or incubators; drugs were kept 
in locked cabinets.  Flammable chemicals (waste alcohols) were stored in a fume 
cupboard.   The biohazard bags were autoclaved prior to removal by NSU clinical waste 
services and all other items were sterilized and the equipment was cleaned. 
 
2.16 Statistical analysis and data management 
This study involved a total of 54 experimental treatment groups and five specific 
aims:  To avoid introducing any unconscious experimenter bias into the data, the raw 
data was collected in a de-identified manner. After the data collection was complete; I 
identified the data treatment groups.  Then, the data was entered into statistical 
spreadsheets for statistical analysis (Statview, SAS, Cary NC).  
To complete specific aim 1:  I counted the migration of osteoblasts and 
osteoclasts in Transwell migration chambers, in response to S1P, TGF-β1, and BMP-2, 
with or without inhibitors: FTY720, K02288, A83-01, and Sclerostin.  The osteoblasts 
and osteoclasts cells that migrated in each of the samples were in the form of real 
continuous numbers, which were analyzed by Analysis of Variance (ANOVA) to 
compare the differences between treatment groups.  
To complete specific aim 2:  I counted the numbers of proliferated osteoblasts 
and osteoclasts in response to bioactive molecules (S1P, TGF-β1, BMP-2) bioactive 
inhibitors (FTY720, K02288, A83-01, and Sclerostin) and osteoclast inhibitors (M5939, 
Osteostatin, Odanacatic, Carfilzomib, Phloretin, Decitabine, Amiloride, Osteoprotegerin, 
Tacrolimus, Cabozantinib, Cathepsin inhibitor, GM 6001 and Osteostatin) using a 
Lactate Dehydrogenase assay (LDA).  The LDA was measured by absorbance using a 
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spectrophotometer.  The LDA data was collected in the form of real continuous 
numbers, which was analyzed by Analysis of Variance (ANOVA) to compare the 
differences between treatment groups. 
To complete specific aim 3, I investigated and compared the mineralization of 
bone by Osteoblasts using a spectrophotometer mineralization assay in response to 
growth factors and bioactive inhibitors.   
To complete specific aim 4:  I used a Collagen resorption assay to investigate the 
collagen degradation activity of osteoclasts in response to bioactive molecules (S1P, 
TGF-β1, BMP-2) bioactive inhibitors (FTY720, K02288, A83-01, and Sclerostin) and 
osteoclast inhibitors (M5939, Osteostatin, Odanacatic, Carfilzomib, Phloretin, 
Decitabine, Amiloride, Osteoprotegerin, Tacrolimus, Cabozantinib, Cathepsin inhibitor, 
GM 6001 and Osteostatin).  
To complete specific aim 5, I compared the mean overall bioactive effects of 












3.1.1. Comparison of cell phenotypes. 
 The immortalized Osteoblasts (Figure 2) immortalized Osteoclasts (Figure 3), 
Osteosarcoma cells (Figure 4), Bone monocytes (Figure 5), mouse alveolar fibroblasts 
(Figure 6), and L929 fibroblasts (Figure 7) all shared a similar round phenotype and cell 
size.  Some of the Periodontal ligament cells appeared to have a round phenotype and 
others had a triangular star-shaped phenotype (Figure 8).  The immature Periodontal 
ligament cells probably had the round phenotype, because many were floating free in 
the media, and the more mature cells probably have the triangular phenotype as they 
attach to the plastic and grow older. Evidently, the different origins and functions of the 
cells, as well as their maturity, could influence their phenotypes. 
 
3.2.1. Cells attached to the migration filters. 
 I and another researcher counted the numbers of cells attached to the transwell 
migration filters from photographs (Figures 9 to 296 appendices).  A digital camera 
attached to a microscope viewing the migration specimens at x200 magnification was 
used to take photographs.  The length viewed by the microscope in each photograph 
was 0.0048mm. The area viewed under the microscope was 0.00002304 mm2. 
 
3.2.2. Stimulation of Osteoblast and Osteoclast migration with growth factors. 
 The mean migration of all the Osteoblasts in response to all the growth factors in 
my study was 0.625 (migrated cells within pores of the migration filters per unit area),  
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and the mean migration of all the Osteoclasts was 34.4% less at 0.410 (migrated cells 
within pores of the migration filters per unit area), (Figure 297).  Although there was a 
mean migration difference of 34.4%, the migration of the osteoblasts and osteoclasts 
were similar (ANOVA P > 0.1395).  The power of the P value was weak at 0.298, 
suggesting that the P value could become significantly different if I were to increase the 
numbers of samples beyond the 288 that I had analyzed. 
 
3.2.3. Stimulation of Osteoblast and Osteoclast migration with individual growth 
factors. 
 The lowest migration of Osteoblasts in my study was 0.056 (mean number of 
migrated cells within pores of the migration filters per unit area), without growth factors 
(as a negative control) (Figure 298).  The greatest migration of Osteoblasts in my study 
was 1.667 (mean number of migrated cells within pores of the migration filters per unit 
area) in response to S1P, which is an increase of 2,976.79% compared to the control 
(Figure 298).  Fewer Osteoblasts migrated in response to TGF-B1 and BMP-2, which 
were 892.86% and 364.29% of the control respectively (Figure 298).  The migration of 
Osteoblasts varied in response to growth factors (ANOVA P < 0.0001, Power 1). The 
lowest migration of Osteoclasts in my study was 0.037 (mean number of migrated cells 
within pores of the migration filters per unit area), in response to BMP-2.  Surprisingly, 
the absence of growth factors in my study as a negative control, did not stimulate the 
lowest migration of Osteoclasts, which was 0.111 or 300% of the Osteoclast response 
to BMP-2.   
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The bar chart shows the mean numbers of osteoblasts and osteoclasts, which migrated 
within the pores of the migration membranes.  I collected this data by counting the cells 
within the membrane filter pores per photograph area.  The error bars show the 










































































































The bar chart shows the mean numbers of Osteoblasts and Osteoclasts which migrated 
within the pores of the migration membranes in response to growth factors.  I collected 
this data by counting the cells within the membrane filter pores per photograph area.  














































































































Growth factors and cell type 
ANOVA P < 0.0001 










The greatest migration of Osteoclasts in my study was 1.111 (mean number of 
migrated cells within pores of the migration filters per unit area) in response to S1P, 
which is an increase of 3,002.7% compared to the BMP-2 (Figure 298).  Fewer 
Osteoclasts migrated in response to TGF-B1, which were 0.417 or 1,127.0% compared 
to the BMP-2 (Figure 298).  The migration of Osteoclasts varied in response to growth 
factors (ANOVA P < 0.0001, Power 0.997). 
 
3.2.4. Inhibition of Osteoblast and Osteoclast migration by bioactive inhibitors. 
The most effective bioactive inhibitor of Osteoblast and Osteoclast migration was 
Sclerostin.  Sclerostin inhibited 94.15% of the migration of Osteoblasts, when compared 
to the negative control (no inhibitor) (0.958 mean) (Figure 299).  Sclerostin inhibited 
100% of the migration of Osteoclasts, when compared to the negative control (no 
inhibitor) (0.722 mean) (Figure 299).  The least potent bioactive inhibitor of Osteoblast 
migration was A83-01 (0.722 mean and 24.63% inhibition compared to control).  The 
most potent bioactive inhibitors of Osteoclast migration were FTY720 (88.41% inhibition 
compared to control) and K02288 (70.09% inhibition compared to control) (Figure 299).  
Sclerostin completely inhibited Osteoclast migration (100% inhibition compared to 
control) (Figure 299).  The less potent inhibitors of Osteoclast migration were FTY720 
(76.87% inhibition compared to control), K02288 (84.62% inhibition compared to 






























The bar chart shows the mean numbers of Osteoblasts and Osteoclasts which migrated 
within the pores of the migration membranes in response to bioactive inhibitors.  I 
collected this data by counting the cells within the membrane filter pores per photograph 
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0.111 0.167 0.111 
0.722 
0.000 
ANOVA P < 0.0165 (Osteoclasts) 
Cell type  
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3.2.5. Inhibition of Osteoblast and Osteoclast migration by bioactive inhibitors 
and individual growth factors. 
 The most potent growth factor to stimulate migration in the absence of inhibitors 
was S1P, followed by TGF-B1 and finally BMP-2 (Figure 300).  In the absence of growth 
factors, only a few cells migrated into the migration filter pores (Figure 300).  Specific 
inhibitors appeared to act on certain growth factors. As an example: Sclerostin 
appeared to be an effective inhibitor of BMP-2.  K02288 was not a very effective 
inhibitor of BMP-2.  FTY720 was an effective inhibitor of S1P.  A83-01 was not a very 
effective inhibitor of TGF-B1 (Figure 300). 
  
3.2.6. Comparison of inhibitors on Osteogenic migration.  
Most combined Osteoblast and Osteoclast migration was observed when no 
bioactive inhibitors were present, compared to the combined effects of growth factors 
(ANOVA P < 0.0001).  The addition of all the bioactive inhibitors reduced cell migration 










Figure 300.  Osteoblast and Osteoclast migration in response to individual inhibitors and 

























The bar chart shows the mean numbers of osteoblasts and osteoclasts, which migrated 
within the pores of the migration membranes in response to bioactive inhibitors and 
individual growth factors.  I collected this data by counting the cells within the 
membrane filter pores per photograph area.  The error bars show the standard deviation 
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The bar chart shows the mean numbers of both osteoblasts and osteoclasts, which 
migrated within the pores of the migration membranes in response to all the bioactive 
inhibitors.  I collected this data by counting the cells within the membrane filter pores per 











































































Addition of bioactive inhibitors  
0.840 
0.194 
ANOVA P < 0.0001 
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3.2.7. Comparison of inhibitors on Osteoblast and Osteoclast migration.  
More combined Osteoblast and Osteoclast migration occurred when no bioactive 
inhibitors were present (ANOVA P < 0.0001).  The addition of inhibitors reduced 
Osteoblast migration by 69.52% and Osteoclast migration by 86.57% (Figure 302).  
When the difference between Osteoblast and Osteoclast migration was analyzed 
including the addition of inhibitors, because of the large variation in the data, the P 
values became similar (ANOVA P < 0.8824) (Figure 302)  
 
3.2.8. Comparison of growth factors with and without inhibitors on Osteogenic 
migration.  
A greater amount of osteogenic migration occurred when no bioactive inhibitors 
were present (ANOVA P < 0.0001).  The addition of bioactive inhibitors in the presence 
of S1P reduced cell migration by 94.73% (Figure 303).  The addition of bioactive 
inhibitors in the presence of TGF-B1 reduced cell migration by 16.6% (Figure 303).  The 
addition of bioactive inhibitors in the presence of BMP-2 reduced cell migration by 




























The bar chart shows the mean numbers of osteoblasts or osteoclasts, which migrated 
within the pores of the migration membranes in response to all the bioactive inhibitors. I 
collected this data by counting the cells within the membrane filter pores per photograph 






































































Addition of bioactive inhibitors  





ANOVA for inhibitor and cell type P < 0.8824 
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The bar chart shows the mean numbers of either osteoblasts or osteoclasts, which 
migrated within the pores of the migration membranes in response to all the bioactive 
inhibitors and growth factors.  I collected this data by counting the cells within the 
membrane filter pores per photograph area.  The error bars show the standard deviation 

















































































0.139 0.111 0.083 
ANOVA for bioactive inhibitor P < 0.0002 
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3.2.9. Comparison of bioactive inhibitors on Osteoblast and Osteoclast migration 
responses to individual growth factors.  
A greater amount of Osteoblast and Osteoclast migration were observed when 
no bioactive inhibitors were present (ANOVA P < 0.0001) (Figure 304).  The most 
effective inhibitor appeared to be Sclerostin because it reduced migration of both 
Osteoblasts and Osteoclasts to zero or nearly zero (Figure 304).  The other inhibitors: 
A83-01, FTY720 and K02288 were significantly reduced the migration of both 
Osteoblasts and Osteoclasts in response to growth factors; S1P, TGF-B1, and BMP-2 
(Figure 304).  
 
3.3.1. Osteoblast and Osteoclast proliferation responses to growth factors. 
 The mean proliferation of the Osteoclasts was 322% greater in comparison to the 
Osteoblasts (ANOVA P < 0.0001) (Figure 305).   
 
3.3.2. Osteoblast and Osteoclast proliferation responses to individual growth 
factors. 
 Osteoclast proliferation was greatest in the absence of all growth factors, 
compared to the proliferation of Osteoclasts in the presence of growth factors: S1P, 
TGF-B1 and BMP-2 (Figure 306).  The proliferation of Osteoblasts in the absence of 
growth factors was similar to their proliferation in the presence of growth factors: S1P, 
TGF-B1 and BMP-2 (Figure 306).   
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Figure 304.  Osteoblast and Osteoclast migration in response to individual inhibitors and 




















The bar chart shows the mean numbers of osteoblasts or osteoclasts, which migrated 
within the pores of the migration membranes in response to individual bioactive 
inhibitors, and individual growth factors.  I collected this data by counting the cells within 
the membrane filter pores per photograph area.  The error bars show the standard 
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The bar chart shows the mean numbers of osteoblasts or osteoclasts, which proliferated 
in response to all the bioactive inhibitors and all the growth factors.  I collected this data 
by counting the cells within the membrane filter pores per photograph area.  The error 
























































The bar chart shows the mean numbers of osteoblasts and osteoclasts, which 
proliferated in response to all the bioactive inhibitors and all the individual growth 
factors.  I collected this data using a MTT cell proliferation assay using a 
spectrophotometer at an absorbance of 595nm.  The error bars show the standard 















































3.3.3. Osteoblast and Osteoclast proliferation responses to individual bioactive 
inhibitors. 
 The proliferation of the Osteoclasts was usually greater than the proliferation of 
Osteoblasts for all of the bioactive inhibitors (Figure 307).  The least proliferation of 
Osteoblasts occurred in the presence of GM6001, and the most proliferation occurred in 
the presence of Phloretin (Figure 307).  The least proliferation of Osteoclasts occurred 
in the presence of Tacrolimus, and the most proliferation occurred in the presence of 
Amiloride (Figure 307).   
 
3.3.4. Osteoblast and Osteoclast proliferation responses to individual growth 
factors and bioactive inhibitors. 
 The proliferation of the Osteoclasts was nearly always greater than the 
proliferation of Osteoblasts for all of the bioactive inhibitors (Figure 308).  The least 
proliferation of Osteoblasts occurred in the presence of GM6001 without a growth factor 
(25.8%), and the most proliferation occurred in the presence of Phloretin without a 
growth factor (322%), (Figure 308).  The least proliferation of Osteoclasts occurred in 
the presence of tacromilus (figure 308) without a growth factor (54%), and the most 
proliferation occurred in the presence of Amiloride without a growth factor (968.5%) 
























The bar chart shows the mean numbers of osteoblasts and osteoclasts, which 
proliferated in response to all the bioactive inhibitors and all the individual growth 
factors.  I collected this data using a MTT cell proliferation assay using a 
spectrophotometer at an absorbance of 595nm.  The error bars show the standard 








































































































































































Figure 308.  Osteoblast and Osteoclast proliferation in response to growth actors in the 

















The bar chart shows the mean numbers of osteoblasts and osteoclasts, which 
proliferated in response to all the bioactive inhibitors and all the individual growth 
factors.  I collected this data using a MTT cell proliferation assay using a 
spectrophotometer at an absorbance of 595nm.  The error bars show the standard 















































































































































































3.4.1. Osteoblast mineralization in response to growth factors. 
 Osteoblast mineralization increased by 198.5% in the presence of growth factors 
(Figure 309), indicating that the addition of growth factors promoted Osteoblast 
mineralization. 
 
3.4.2. Osteoblast mineralization in response to bioactive inhibitors. 
Osteoblast mineralization decreased by 39.2% in the presence of bioactive 
inhibitors (Figure 310), indicating that the addition of bioactive inhibitors reduced 
Osteoblast mineralization. 
 
3.4.3. Osteoblast mineralization in response to growth factors and bioactive 
inhibitors. 
Osteoblast mineralization was least where there were no growth factors and the 
presence of bioactive inhibitors (Figure 311).  Osteoblast mineralization was greater 
where there were no bioactive inhibitors.  Although it appears that there was slightly 
more mineralization without growth factors, the mineralization was similar with growth 
factors (Figure 311).  These results suggest that the bioactive inhibitors suppress 
mineralization, even when growth factors are promoting mineralization. 
 
3.4.4. Osteoblast mineralization in response to individual growth factors. 
Osteoblast mineralization was dependent on the presence of growth factors 
(ANOVA P < 0.0001).  Osteoblast mineralization was highest in the presence of S1P 
(139% of the control), and lower in the presence of TGF-B1 (44%) no growth factor 
(control) (34%), and the lowest mineralization occurred in the presence of BMP-2 
(Figure 312).  
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The bar chart shows the mean percentage of mineralization created by osteoblasts in 
response to growth factors.  I measured the mineralization within my samples using a 
spectrophotometer at an absorbance of 595nm.  The error bars show the standard 














































































The bar chart shows the mean percentage of mineralization created by osteoblasts in 
response to bioactive inhibitors.  I measured the mineralization within my samples using 
a spectrophotometer at an absorbance of 595nm.  The error bars show the standard 












































































The bar chart shows the mean percentage of mineralization created by osteoblasts in 
response to growth factors.  I measured the mineralization within my samples using a 
spectrophotometer at an absorbance of 595nm.  The error bars show the standard 






























































ANOVA P < 0.0001 
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The bar chart shows the mean percentage of mineralization created by osteoblasts in 
response to individual growth factors.  I measured the mineralization within my samples 
using a spectrophotometer at an absorbance of 595nm.  The error bars show the 
























































ANOVA P < 0.0001 
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3.4.5. Osteoblast mineralization in response to individual bioactive inhibitors. 
The amount of Osteoblast mineralization was dependent on the presence of 
bioactive inhibitors (ANOVA P < 0.0001).  Osteoblast mineralization (as a percentage of 
the control) was highest in the presence of Phloretin (138%), FTY720 (76.3%), A83-01 
(48.6%), Carbozantnib (40.6%), Amiloride (22.1%), Tacrolimus (14.8%), Odanacatib 
(13.8%), M5939 (13%), GM6001 (12%), K02288 (11.8%), Osteostatin (11.1%), 
Carfilzomib (11%), Osteoprotegerin (10.8%), Decitabine (10.7%), and Cathepsin 
inhibitor (10.4%) (Figure 313).   
 
3.5.1. Osteoclast collagen degradation responses to bioactive inhibitors. 
The presence of bioactive inhibitors had an effect on the degradation of Collagen 
by Osteoclasts (ANOVA P < 0.0027).   The amount of non-degraded collagen was 
69.91% greater after bioactive inhibitors were added to the Osteoclast cell cultures 
(Figure 314).    
 
3.5.2. Osteoclast collagen degradation responses to growth factors. 
The presence of growth factors had an effect on the degradation of Collagen by 
Osteoclasts (ANOVA P < 0.0194).  The amount of non-degraded collagen was 59.16% 
























The bar chart shows the mean percentage of mineralization created by osteoblasts in 
response to individual bioactive inhibitors.  I measured the mineralization within my 
samples using a spectrophotometer at an absorbance of 595nm.  The error bars show 






































































































































































































































The bar chart shows the mean percentage of non-degraded collagen by Osteoclasts in 
response to bioactive inhibitors.  I measured the amount of non-degraded Mouse tail 
type-1 collagen within my samples using a spectrophotometer at an absorbance of 





























































































The bar chart shows the mean percentage of non-degraded collagen by Osteoclasts in 
response to growth factors.  I measured the amount of non-degraded Mouse tail type-1 
collagen within my samples using a spectrophotometer at an absorbance of 595nm.  
































































3.5.3. Osteoclast collagen degradation responses to individual bioactive 
inhibitors. 
The presence of individual bioactive inhibitors had an effect on the degradation of 
Collagen by Osteoclasts (ANOVA P < 0.0001).  The greatest amount of non-degraded 
collagen occurred in the presence of FTY720 (568.7%) and the least amount of non-
degraded collagen occurred in the presence of Decitabine (88.958%) (Figure 316). 
The rank order of bioactive inhibitors from having the greatest effect to inhibit 
collagen degradation by Osteoclasts to the least effective, as a percentage of the 
control are: FTY720 (568.7%), Carfilzomib (371.186%), Phloretin (273.189%), Amiloride 
(271.731%), Cathepsin inhibitor (143.093%), Tacrolimus (138.942%), GM6001 
(136.554%), A83-01 (136.234%), K02288 (130.913%), Carbozantnib (130.737%), 
Osteostatin (121.731%), M5939 (118.862%), Osteoprotegerin (107.869%), and 
Decitabine (88.958%) (Figure 316). 
 
3.5.4. Osteoclast collagen degradation responses to individual growth factors. 
Collagen degradation by Osteoclasts was least without growth factors.  In the 
presence of growth factors’ the amount of collagen degradation increased.  The 
increase in collagen degradation was similar among the growth factors; S1P (116.1%), 
TGF-B1 (119.3%) and BMP-2 (114.0%) (ANOVA P < 0.1423).  Compared to a lack of 
growth factor, the presence of S1P increased collagen degradation by 59.6%, TGF-B1 

































The bar chart shows the mean percentage of non-degraded collagen by Osteoclasts in 
response to growth factors.  I measured the amount of non-degraded Mouse tail type-1 
collagen within my samples using a spectrophotometer at an absorbance of 595nm.  














































































































































































































ANOVA P < 0.0001 
Bioactive inhibitors 
 98




























The bar chart shows the mean percentage of non-degraded collagen by Osteoclasts in 
response to growth factors.  I measured the amount of non-degraded Mouse tail type-1 
collagen within my samples using a spectrophotometer at an absorbance of 595nm.  
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3.6.1. Results summary of the effects of individual growth factors. 
Overall, the most potent growth factor was S1P (mean 733.6), and the least 
potent growth factor was BMP-2 (mean 51.5) (Table 4).  A comparison of the effects of 
the individual growth factors; S1P, TGF-B1, and BMP-2 with the control mean, in the 
migration, proliferation, mineralization, and collagen degradation assays found that they 
had a diverse range of effects on Osteoblast and Osteoclast activity, as shown in   
Table 4. 






















effect in all 
assays 
S1P 2,976.8% 1,000.9% 14.6% -58.4% 408.3% 59.6% 733.6 
TGF-B1 892.9% 375.7% -8.7% -71.0% 29.0% 55.4% 212.2 
BMP-2 364.3% 33.3% -42.0% -66.1% -41.5% 62.5% 51.5 
 
 
3.6.2. Results summary of the effects of individual bioactive inhibitors. 
Overall, the most potent bioactive inhibitor was Amiloride (mean 344.4), and the 
least potent inhibitor was GM6001 (mean -19.0) (Table 5).  A comparison of the effects 
of the individual bioactive inhibitors; FTY720, K02288, A83-01, M5939, Osteostatin, 
Sclerostin, Odanacatic, Carfilzomib, Phloretin, Decitabine, Amiloride, Osteoprotegerin, 
Tacrolimus, Cabozantinib, Cathepsin inhibitor, GM 6001 and Osteostatin with each 
control mean, in the migration, proliferation, mineralization, and collagen degradation 
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assays found that they had a diverse range of effects on Osteoblast and Osteoclast 
activity, as shown in   Table 5.   
























effect in all 
assays 
Sclerostin * 94.2% 100% - - - - 97.1 
FTY720 88.4% 76.9% 71.8% 567.887% 76.3% 506.3% 134.2 
Carfilzomib - - -3.6% 346.2% 11.0% 330.4% 171.0 
Phloretin - - 394.2% 474.1% 138.0% 243.2% 312.4 
Amiloride - - 314.8% 898.6% 22.1% 241.9% 344.4 
Cathepsin 
inhibitor 
- - -38.7% 293.0% 10.4% 27.4% 292.1 
Tacrolimus - - -46.6% 49.4% 14.8% 23.7% 10.3 
GM6001 - - -69.4% -40.2% 12.0% 21.6% -19.0 
A83-01 24.6% 84.6% -56.6% -36.3% 48.6% 21.3% 14.4 
K02288 70.1% 84.6% -54.5% 4.7% 11.8% 16.5% 22.2 
Carbozantnib - - -68.1% 300.2% 40.6% 16.3% 72.3 
Osteostatin - - -11.1% -35.4% 11.1% 8.4% -6.75 
M5939 - - -66.5% 216.3% 13.0% 5.8% 42.2 
Osteoprotegerin - - -7.6% -38.0% 10.8% -4.0% -9.7 
Decitabine - - -31.8% 814.2% 10.7% -20.8% 193.1 
Odanacatic - - -40.2% 333.8% 13.8% 12.1% 79.9 
Note: *The Sclerostin supplies were consumed by the migration experiments.  No Sclerostin was 
available for testing in the proliferation, migration or collagen degradation assays. 
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4.  DISCUSSION 
          This is the first and most comprehensive study of its kind to investigate the 
migration, proliferation, mineralization, and degradation activity of Osteoblasts and 
Osteoclasts.  Bone maintenance, healing, regeneration, and bone defect repair is 
dependent on the regenerative capacity of Osteoblasts.  Bone resorption, osteoporosis, 
peri implantitis and bone loss can be caused by the activity of Osteoclasts (1).  It is the 
balance in activity between bone regeneration by Osteoblasts and bone resorption by 
Osteoclasts, which determines if bone regeneration or bone loss occurs.  Osteoblast 
and Osteoclast cells respond to growth factors and bioactive inhibitors within the local 
environment, and the concentrations of these molecules may help determine if bone 
loss or bone regeneration occurs (107).  To develop new therapies which can promote 
bone regeneration and avoid bone resorption I have accomplished the objectives of my 
research, by investigating the effects of several growth factors (S1P, TGF- B1, BMP-2) 
and bioactive inhibitors (FTY720, K02288, A83-01, M5939, Osteostatin, Sclerostin, 
Odanacatic, Carfilzomib, Phloretin, Decitabine, Amiloride, Osteoprotegerin, Tacrolimus, 
Cabozantinib, Cathepsin inhibitor, GM 6001 and Osteostatin) their effects on 
Osteoblasts and Osteoclasts, using migration, proliferation, osteogenic mineralization, 
and collagen degradation, to identify information which could be used to develop novel 
scaffolds, fillers, and membranes to repair bone defects.  My research comprised of 





4.1. Successful immortalization of Osteoblasts and Osteoclasts. 
 I attempted to immortalize several Osteoblast cell lines (including CRL-1427, 
CRL-11372, hFOB 1.19) and Osteoclast cells (including PCS-900-010), many of which 
proved to be of limited usefulness because the cells died before the assay 
experimentation for my thesis could begin.  My numerous unsuccessful attempts to 
immortalize Osteoblast and Osteoclast cell lines, demonstrates the difficulty in creating 
new cell lines for experimentation, similar to the technical difficulty encountered by 
previous investigators (120).  Cell replicative senescence due to short telomeres and 
p16 induced by culture stress can inhibit cell growth (121).  I used the forced expression 
of telomerase (hTERT) to prevent replicative senescence, and expression of the cell 
cycle protein cdk4 to sequester p16, to immortalize cells in culture (121).  Using this 
technique, I was eventually able to immortalize an Osteoblast cell line called CRL-1127-
LTX and an Osteoclast cell line called RAW264.7-LTX.  I used these two immortalized 
cells in my assays, because they had an extended lifespan.  My immortalized 
Osteoblasts and Osteoclasts, enabled me to complete all the migration, proliferation, 
mineralization, and collagen degradation experiments, without encountering cell death, 
which has been a limiting factor in previous studies (122).  Although these cells are now 
considered to be immortalized, it does not however mean that these cells will live 
forever, or are immortal, because all cell cultures have a limited ability to grow cells 
dues to restrictions in nutrients, toxic waste accumulation in culture, infection and 
contamination risks, and failure of environmental conditions to mimic the in situ whole 
body environment (123).  An advantage of the immortalized Osteoblasts and 
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Osteoclasts that I have created as part of my research is that they can be used for 
future investigations, to help create bone regeneration materials and therapies. 
 
4.2. Phenotype of Osteoblasts and Osteoclasts. 
 The phenotype (shape) of Osteoblasts and Osteoclasts can be grouped into 
three types:  i) Round cells.  ii) Oblong cells, and, iii) Flattened and star-shaped 
(spindle) cells.  These phenotypes were described by Al-Nazhan (124).  The histological 
architecture of cells is not completely correlated with cell activity and functioning, 
although it may indicate intracellular changes in gene expression and protein production 
(125). Nevertheless, the phenotype of a cell can provide an indicator of its interactions 
with its local environment.  Normally completely round cells, are most likely to be 
immature, and are not located in an environment where they wish to attach, whereas, 
flattened and star-shaped cells are more likely to be mature, and are more likely to be in 
an environment where they wish to attach (126).  Based on my phenotypic 
observations, the Osteoblasts were almost all rounded, suggesting they were not 
activated, or in a favorable environment to interact with substrates.  Conversely, the 
Osteoclasts were mostly rounded, but a few were flattened and triangular, suggesting 
they were more likely to be more actively involved with their environment.  Some 
research has indicated that macrophages have different growth requirements to 
Osteoclasts, but that they derive from a common progenitor cell (127).  The different 
growth requirements of Osteoblasts, Osteoclasts, growth factors, bioactive inhibitors, 
extracellular matrix proteins, infection by pathogens and chronic inflammatory events 
may explain how osteonecrosis, osteoporosis, and periimplantitis can develop (128). 
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4.3.  Migration responses of Osteoblasts and Osteoclasts to growth factors and 
bioactive inhibitors. 
I investigated and compared the migration responses of immortalized Osteoblast 
and Osteoclast cells in response to three growth factors and four bioactive inhibitors 
using a transwell migration assay.  The migration of the Osteoblasts and Osteoclasts in 
response to the growth factors: S1P, TGF-B1, and BMP-2 were similar (Figure 297), 
suggesting both the cell types had a similar capacity to migrate in response to growth 
factors.  A study of cell co-cultures of Osteoblasts and Osteoclasts in a transwell 
migration assay, found that these cells interact with each other and epithelial cells to 
contribute to bone destruction (129), which suggests that these cells can migrate in 
competition with each other at the site of a bone defect.   
I discovered that S1P was the most effective promoter of Osteoblast and Osteoclast 
migration, because S1P increased migration by almost 3,000% and 1,000% 
respectively (Figure 298).   A search of Entrez Medline did not reveal any related study 
on Osteoblasts and Osteoclasts for comparison.  Nevertheless, previous research from 
NSU, had discovered that S1P promoted more vigorous dental pulp stem cell migration 
in comparison to TGF-B1 (114).  While the previous study did not investigate 
Osteoblasts or Osteoclast migration, it demonstrated as observed here, that S1P is 
among the most potent migration signaling molecules (114).  My results reinforce the 
previous observations that S1P is of importance in the entire human body, it is a major 
regulator of the migration (trafficking) and differentiation of immune cells from the 
vascular system into injured tissues or sites of infection or disease (24).  My results 
reinforce the previous observation that blocking S1P receptors and pathways, could 
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help prevent the migration/metastasis of cancerous cells (130).  My results also suggest 
that bone regeneration scaffolds can be developed which target the intracelular 
sphingosine kinase 1 (SK1)/sphingosine-1-phosphate (S1P) signaling pathway (131) to 
anchor osteoblasts and to promote osteoclast migration away from bone defects to 
accomplish osteogenic regeneration. 
The most effective inhibitor of Osteoblast (94%) and Osteoclast (100%) migration was 
Sclerostin.  Sclerostin has not been widely studied; it is a secreted glycoprotein 
encoded by the SOST gene (132).  Sclerostin is a secreted glycoprotein with a C-
terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN 
(differential screening-selected gene aberrative in neuroblastoma) family of BMP 
antagonists.  Sclerostin can be produced by osteocyte cells and has anti-anabolic 
effects on bone formation (133).  Sclerostin can inhibit the Wnt signaling pathway (134), 
leading to decreased bone formation (134). The antagonism of BMP-induced bone 
formation by Sclerostin can be mediated by Wnt signaling, but not BMP signaling 
pathways.  Sclerostin is expressed in Osteocytes and some Chondrocytes and it can 
inhibit bone formation by osteoblasts (135).  My novel discovery that Sclerostin is an 
effective inhibitor of Osteoblast and Osteoclast migration is supported by a study which 
found that a down-regulated a genetic sequence called “sclerostin domain containing 





4.4.  Proliferation responses of Osteoblasts and Ostoeclasts to growth factors 
and bioactive inhibitors. 
I investigated and compared the proliferation of immortalized Osteoblast and 
Osteoclast cells using a MTT assay and spectrophotometer in response to growth 
factors and bioactive inhibitors.  I observed that Phloretin was the most effective 
promoter of Osteoblast proliferation (394%), and that Amiloride was the most effective 
promoter of Osteoclast proliferation (899%).   A previous study found that Phloretin was 
effective in preventing estrogen deficiency-induced osteoclastogenic resorption (47). 
The most effective inhibitor of Osteoblast proliferation was GM6001 (-69%), and the 
most effective inhibitor of Osteoclast proliferation was Tacrolimus (Figure 307).  
 
4.5.  Osteoblast mineralization responses to growth factors and bioactive 
inhibitors. 
I investigated and compared the mineralization of bone by Osteoblasts using a 
mineralization assay and spectrophotometer in response to growth factors and bioactive 
inhibitors.  I observed that S1P was the most effective promoter of Osteoblast 
mineralization (408%). 
 
4.6.  Osteoclast degradation of collagen in response to growth factors and 
bioactive inhibitors. 
I investigated and compared the degradation of Collagen by Osteoclasts using a 
Mouse Tail Collagen Type-1 degradation assay and spectrophotometer in response to 
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growth factors and bioactive inhibitors.  I observed that FTY720 was the most effective 
compound at preventing collagen degradation (506%). 
 
4.7.  Development of bioactive scaffolds. 
 I hypothesized that a scaffold comprising of S1P, Phloretin, and FTY720 could be 
developed to be implanted into bone defects and empty tooth sockets to promote bone 
regeneration, and to prevent osteonecrosis, osteoporosis, and periimplantitis.  This, is 
my recommendation for future research in laboratory, animal and in clinical trials.   
 
4.8.  Conclusions. 
 My sincere hope is that patients, the dental profession, and manufacturers of 
osteoregenerative materials, scaffolds and membranes will benefit from my study data.  
The treatment of bone defects, fractures, and infected bone has always proved to be 
difficult because of the long time it takes (months and years) to regenerate new 
replacement bone.  Clearly a new generation of bioactive bone repair materials, 
scaffolds and membranes have the potential to increase the speed and effectiveness of 
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Figure 49.   Migration of osteoblast in response to S1P as bioactive molecules 
and without inhibitors 
 
 









































































































































Figure 81.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 82.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 83.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 84.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 85.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 86.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 87.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 88.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 89.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 90.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 91.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 92.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 93.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 94.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 95.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 96.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 97.  Migration of osteoblast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 98.  Migration of osteoblast in response to S1P as bioactive molecules 




Figure 99.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 100.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
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Figure 101.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 102.  Migration of osteoclast in response to S1P as bioactive molecules 




Figure 103.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 104.  Migration of osteoclast in response to S1P as bioactive molecules 




Figure 105.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 106.  Migration of osteoclast in response to S1P as bioactive molecules 





Figure 107.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 108.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
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Figure 109.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 110.  Migration of osteoclast in response to S1P as bioactive molecules 




Figure 111.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 112.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
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Figure 113.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 114.  Migration of osteoclast in response to S1P as bioactive molecules 




Figure 115.  Migration of osteoclast in response to S1P as bioactive molecules 
inhibited by FTY720 
 
 
Figure 116.  Migration of osteoclast in response to S1P as bioactive molecules 




Figure 117.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 118.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 119.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 120.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 121.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 122.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 123.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 124.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 125.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 126.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 127.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 128.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 129.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 130.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 131.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 132.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 133.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 134.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 





Figure 135.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 136. Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
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Figure 137.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 138.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 





Figure 139.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 140.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 141.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 142.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 143.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 144.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 145.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 146.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 147.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 148.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 149.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 150.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 151.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
without inhibitor  
 
 
Figure 152.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 153.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 154.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 155.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 156.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 157.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 158.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
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Figure 159.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 160.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 161.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 162.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 163.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 164.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 165.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 166.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 167.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 168.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 169.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 170.  Migration of osteoblast in response to TGF- β1 as bioactive molecule 




Figure 171.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 172.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 173.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 174.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 175.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 176.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 177.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 178.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 179.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 180.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 181.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 182.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 183.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 184.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 185.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 186.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 187.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 
inhibited by A83-01 
 
 
Figure 188.  Migration of osteoclast in response to TGF- β1 as bioactive molecule 




Figure 189.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 190.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 191.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 192. Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 193.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor  
 
 
Figure 194.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 195.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 196.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 197. Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 198.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
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Figure 199.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 200.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 201.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 202. Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 203.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 204.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 205.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor  
 
 
Figure 206.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
without an inhibitor 
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Figure 207.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 208.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 209.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 210.   Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 211.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 212.   Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 213.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 214.   Migration of osteoclast in response to BMP-2 as bioactive molecule 





Figure 215.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 216.   Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 217.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 218.   Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 219.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 220.   Migration of osteoclast in response to BMP-2 as bioactive molecule 





Figure 221.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 222.   Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 223.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
 
 
Figure 224.   Migration of osteoclast in response to BMP-2 as bioactive molecule 
without an inhibitor 
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Figure 225.   Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 226.   Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 227.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 228.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 229.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 230.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 231.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 232.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 233.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 234.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 235.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 236.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 237.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 238.  Migration of osteoblast in response to BMP-2 as bioactive molecule 





Figure 239.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 240.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 241.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 242.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
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Figure 243.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 244.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 245.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 246.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 247.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 248.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 249.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 250.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 251.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 252.  Migration of osteoclast in response to BMP-2 as bioactive molecule 





Figure 253.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 254.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
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Figure 255.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 256.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 257.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 258. Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 259.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by K02288 
 
 
Figure 260.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 261.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 262.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
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Figure 263.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 264.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 265.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 266.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 267.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 268.  Migration of osteoblast in response to BMP-2 as bioactive molecule 





Figure 269.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 270.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
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Figure 271.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 272.  Migration of osteoblast in response to BMP-2 as bioactive molecule 





Figure 273.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 274.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 275.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 276.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 277.  Migration of osteoblast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 278.  Migration of osteoblast in response to BMP-2 as bioactive molecule 




Figure 279.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 280.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 281.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 282.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
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Figure 283.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 284.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 285.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 286.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 287.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 288.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
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Figure 289.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 290.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 291.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 292.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 293.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 294.  Migration of osteoclast in response to BMP-2 as bioactive molecule 




Figure 295.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
inhibited by Sclerostin 
 
 
Figure 296.  Migration of osteoclast in response to BMP-2 as bioactive molecule 
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Figure 299.  Osteoblast and Osteoclast migration responses to bioactive 
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Figure 300.  Osteoblast and Osteoclast migration in response to individual 








Figure 301.  Effect of all inhibitors to reduce Osteoblast and Osteoclast migration. 
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Figure 303.  Effect of all inhibitors to reduce Osteoblast and Osteoclast migration. 
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Count Mean Std. Dev. Std. Err.
No
Yes
Means Table for Cells
Effect: Inhibitor?
Split By: Bioaactive molecule sequence
Cell: d S1P
A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.
ANOVA Table for Cells
Split By: Bioaactive molecule sequence
Cell: a None
1 .019 .019 .101 .7511 .101 .061
106 19.417 .183
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor?
Residual
ANOVA Table for Cells
Split By: Bioaactive molecule sequence
Cell: b BMP2
1 .125 .125 .122 .7280 .122 .063
70 71.750 1.025
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor?
Residual
ANOVA Table for Cells







Figure 304.  Osteoblast and Osteoclast migration in response to individual 
inhibitors and all the growth factors. 
 
1 112.500 112.500 51.602 <.0001 51.602 1.000
70 152.611 2.180
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor?
Residual
ANOVA Table for Cells
Split By: Bioaactive molecule sequence
Cell: d S1P
.517 1.235 .073 288 0.000 8.000 0 1.526 2.388
.056 .236 .056 18 0.000 1.000 0 .056 4.243
.111 .323 .076 18 0.000 1.000 0 .105 2.910
.278 .575 .135 18 0.000 2.000 0 .330 2.068
0.000 0.000 0.000 18 0.000 0.000 0 0.000 •
.278 .752 .177 18 0.000 3.000 0 .565 2.707
.056 .236 .056 18 0.000 1.000 0 .056 4.243
.111 .323 .076 18 0.000 1.000 0 .105 2.910
0.000 0.000 0.000 18 0.000 0.000 0 0.000 •
.278 .752 .177 18 0.000 3.000 0 .565 2.707
.722 1.074 .253 18 0.000 3.000 0 1.154 1.487
.722 1.447 .341 18 0.000 5.000 0 2.095 2.004
.111 .323 .076 18 0.000 1.000 0 .105 2.910
3.222 1.734 .409 18 0.000 6.000 0 3.007 .538
2.056 2.209 .521 18 0.000 8.000 0 4.879 1.075
.111 .471 .111 18 0.000 2.000 0 .222 4.243
.167 .383 .090 18 0.000 1.000 0 .147 2.301
Mean Std. Dev. Std. Error Count Minimum Maximum # Missing Variance Coef. Var.
Cells, Total
Cells, a None, No, Osteoblasts, none
Cells, a None, No, Osteoclasts, none
Cells, b BMP2, No, Osteoblasts, none
Cells, b BMP2, No, Osteoclasts, none
Cells, b BMP2, Yes, Osteoblasts, K02288
Cells, b BMP2, Yes, Osteoblasts, Sclerostin
Cells, b BMP2, Yes, Osteoclasts, K02288
Cells, b BMP2, Yes, Osteoclasts, Sclerostin
Cells, c TGF-B, No, Osteoblasts, none
Cells, c TGF-B, No, Osteoclasts, none
Cells, c TGF-B, Yes, Osteoblasts, A83-01
Cells, c TGF-B, Yes, Osteoclasts, A83-01
Cells, d S1P, No, Osteoblasts, none
Cells, d S1P, No, Osteoclasts, none
Cells, d S1P, Yes, Osteoblasts, FTY720
Cells, d S1P, Yes, Osteoclasts, FTY720
Descriptive Statistics





A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.
ANOVA Table for Cells
Split By: Bioactive inhibitor
Cell: A83-01
A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.
ANOVA Table for Cells
Split By: Bioactive inhibitor
Cell: FTY720
A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.
ANOVA Table for Cells








3 158.965 52.988 39.806 <.0001 119.419 1.000
140 186.361 1.331
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioaactive molecule sequence
Residual
ANOVA Table for Cells
Split By: Bioactive inhibitor
Cell: none
A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.
ANOVA Table for Cells
Split By: Bioactive inhibitor
Cell: Sclerostin
4 20.931 5.233 3.020 .0200 12.081 .793
139 240.819 1.733
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioactive inhibitor
Residual
ANOVA Table for Cells
Split By: Cell type
Cell: Osteoblasts
4 14.326 3.582 3.141 .0165 12.564 .812
139 158.500 1.140
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioactive inhibitor
Residual
ANOVA Table for Cells
Split By: Cell type
Cell: Osteoclasts
18 .722 1.447 .341
18 .111 .471 .111
18 .278 .752 .177
72 .958 1.640 .193
18 .056 .236 .056






Means Table for Cells
Effect: Bioactive inhibitor






18 .111 .323 .076
18 .167 .383 .090
18 .111 .323 .076
72 .722 1.465 .173
18 0.000 0.000 0.000






Means Table for Cells
Effect: Bioactive inhibitor
Split By: Cell type
Cell: Osteoclasts
A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.
ANOVA Table for Cells
Split By: Bioactive inhibitor
Cell: Sclerostin
Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type






Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type
Cell: a None, Osteoclasts
Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type
Cell: b BMP2, Osteoblasts
Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type





Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type
Cell: b BMP2, Osteoclasts
Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type
Cell: c TGF-B, Osteoblasts
Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type





Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type
Cell: d S1P, Osteoblasts
Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
ANOVA Table for <None>
Split By: Bioaactive molecule sequence, Cell type
Cell: d S1P, Osteoclasts
Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
Means Table for <None>
Split By: Bioaactive molecule sequence, Cell type




Figure 305.  Osteoblast and Osteoclast migration in response to individual 




Assign one or more continuous dependent variables using
the variable brow ser Dependent button.
Means Table for <None>
Split By: Bioaactive molecule sequence, Cell type
Cell: a None, Osteoclasts
.517 1.235 .073 288 0.000 8.000 0 1.526 2.388
.056 .236 .056 18 0.000 1.000 0 .056 4.243
.111 .323 .076 18 0.000 1.000 0 .105 2.910
.278 .575 .135 18 0.000 2.000 0 .330 2.068
0.000 0.000 0.000 18 0.000 0.000 0 0.000 •
.278 .752 .177 18 0.000 3.000 0 .565 2.707
.056 .236 .056 18 0.000 1.000 0 .056 4.243
.111 .323 .076 18 0.000 1.000 0 .105 2.910
0.000 0.000 0.000 18 0.000 0.000 0 0.000 •
.278 .752 .177 18 0.000 3.000 0 .565 2.707
.722 1.074 .253 18 0.000 3.000 0 1.154 1.487
.722 1.447 .341 18 0.000 5.000 0 2.095 2.004
.111 .323 .076 18 0.000 1.000 0 .105 2.910
3.222 1.734 .409 18 0.000 6.000 0 3.007 .538
2.056 2.209 .521 18 0.000 8.000 0 4.879 1.075
.111 .471 .111 18 0.000 2.000 0 .222 4.243
.167 .383 .090 18 0.000 1.000 0 .147 2.301
Mean Std. Dev. Std. Error Count Minimum Maximum # Missing Variance Coef. Var.
Cells, Total
Cells, a None, No, Osteoblasts, none
Cells, a None, No, Osteoclasts, none
Cells, b BMP2, No, Osteoblasts, none
Cells, b BMP2, No, Osteoclasts, none
Cells, b BMP2, Yes, Osteoblasts, K02288
Cells, b BMP2, Yes, Osteoblasts, Sclerostin
Cells, b BMP2, Yes, Osteoclasts, K02288
Cells, b BMP2, Yes, Osteoclasts, Sclerostin
Cells, c TGF-B, No, Osteoblasts, none
Cells, c TGF-B, No, Osteoclasts, none
Cells, c TGF-B, Yes, Osteoblasts, A83-01
Cells, c TGF-B, Yes, Osteoclasts, A83-01
Cells, d S1P, No, Osteoblasts, none
Cells, d S1P, No, Osteoclasts, none
Cells, d S1P, Yes, Osteoblasts, FTY720
Cells, d S1P, Yes, Osteoclasts, FTY720
Descriptive Statistics
Split By: Bioaactive molecule sequence, Inhibitor?, Cell type, Bioactive inhibitor
A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.











1 2922343.263 2922343.263 48.487 <.0001 48.487 1.000
302 18201721.919 60270.602
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Cell Type
Residual
ANOVA Table for Proliferation (% Crtl)
152 88.057 101.020 8.194
152 284.149 332.169 26.942
Count Mean Std. Dev. Std. Err.
a Osteoblasts
b Osteoclasts
Means Table for Proliferation (% Crtl)
Effect: Cell Type
1 3569116.802 3569116.802 56.602 <.0001 56.602 1.000
270 17025186.275 63056.245
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Cell Type
Residual
ANOVA Table for Proliferation (% Crtl)
Split By: Bioactive molecule
Cell: a None
1 3327.839 3327.839 .452 .5121 .452 .094
14 102971.464 7355.105
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Cell Type
Residual
ANOVA Table for Proliferation (% Crtl)
Split By: Bioactive molecule
Cell: b S1P
128 89.759 103.114 9.114
128 316.730 350.305 30.963
Count Mean Std. Dev. Std. Err.
a Osteoblasts
b Osteoclasts
Means Table for Proliferation (% Crtl)
Effect: Cell Type











8 102.906 118.665 41.954
8 131.749 25.079 8.867
Count Mean Std. Dev. Std. Err.
a Osteoblasts
b Osteoclasts
Means Table for Proliferation (% Crtl)
Effect: Cell Type
Split By: Bioactive molecule
Cell: b S1P
8 81.980 98.925 34.975
8 92.100 79.688 28.174
Count Mean Std. Dev. Std. Err.
a Osteoblasts
b Osteoclasts
Means Table for Proliferation (% Crtl)
Effect: Cell Type
Split By: Bioactive molecule
Cell: c TGF-B1
8 52.066 39.258 13.880
8 107.294 151.321 53.500
Count Mean Std. Dev. Std. Err.
a Osteoblasts
b Osteoclasts
Means Table for Proliferation (% Crtl)
Effect: Cell Type
Split By: Bioactive molecule
Cell: d BMP2
186.103 264.039 15.144 304 14.791 968.523 311
89.759 103.114 9.114 128 14.791 363.636 128
102.906 118.665 41.954 8 23.945 363.636 8
81.980 98.925 34.975 8 23.664 283.327 8
52.066 39.258 13.880 8 22.791 144.809 8
316.730 350.305 30.963 128 32.446 968.523 128
131.749 25.079 8.867 8 106.295 172.639 8
92.100 79.688 28.174 8 38.741 257.385 8
107.294 151.321 53.500 8 37.772 477.240 8
Mean Std. Dev. Std. Error Count Minimum Maximum # Missing
Proliferation (% Crtl), Total
Proliferation (% Crtl), a Osteoblasts, a None
Proliferation (% Crtl), a Osteoblasts, b S1P
Proliferation (% Crtl), a Osteoblasts, c TGF-B1
Proliferation (% Crtl), a Osteoblasts, d BMP2
Proliferation (% Crtl), b Osteoclasts, a None
Proliferation (% Crtl), b Osteoclasts, b S1P
Proliferation (% Crtl), b Osteoclasts, c TGF-B1
Proliferation (% Crtl), b Osteoclasts, d BMP2
Results for totals may not agree w ith results for individual cells because of missing values for split variables.
Descriptive Statistics
Split By: Cell Type, Bioactive molecule
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1 3504146.363 3504146.363 150.229 <.0001 150.229 1.000
15 7699872.001 513324.800 22.007 <.0001 330.106 1.000
15 4157331.292 277155.419 11.882 <.0001 178.232 1.000
272 6344518.625 23325.436
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Cell Type
Inhibitor
Cell Type * Inhibitor
Residual
ANOVA Table for Proliferation (% Crtl)
186.103 264.039 15.144 304 14.791 968.523 311
84.231 95.189 16.827 32 22.791 363.636 32
144.680 91.675 32.412 8 88.255 363.636 8
36.563 19.086 6.748 8 20.755 79.691 8
38.347 11.135 3.937 8 22.373 52.182 8
28.228 3.517 1.243 8 24.300 34.582 8
50.385 46.844 16.562 8 26.927 164.027 8
81.200 71.809 25.388 8 31.682 247.027 8
332.065 44.262 15.649 8 264.264 363.636 8
57.419 38.360 13.562 8 20.336 133.836 8
265.192 101.713 35.961 8 94.045 363.636 8
77.855 93.063 32.903 8 18.636 250.236 8
44.949 69.869 24.702 8 14.855 217.718 8
26.866 11.663 4.124 8 16.236 54.591 8
25.800 6.110 2.160 8 14.791 33.391 8
51.669 39.492 13.962 8 26.436 147.464 8
74.950 41.397 14.636 8 43.836 156.200 8
107.786 83.845 14.822 32 37.772 477.240 32
567.887 343.902 121.588 8 231.961 968.523 8
68.674 61.180 21.630 8 32.446 211.380 8
112.863 136.643 48.311 8 37.530 434.140 8
233.111 294.620 104.164 8 44.068 808.232 8
359.746 421.794 149.127 8 47.458 968.523 8
373.184 402.446 142.286 8 50.605 968.523 8
511.047 249.486 88.207 8 289.104 968.523 8
877.633 129.986 45.957 8 654.964 968.523 8
968.523 0.000 0.000 8 968.523 968.523 8
66.840 6.115 2.162 8 58.620 76.247 8
54.528 9.222 3.260 8 38.935 70.508 8
323.735 274.084 96.904 8 150.073 844.988 8
64.495 14.146 5.001 8 51.404 88.765 8
315.763 256.472 90.676 8 145.448 839.709 8
69.655 19.005 6.719 8 38.450 92.760 8
Mean Std. Dev. Std. Error Count Minimum Maximum # Missing
Proliferation (% Crtl), Total
Proliferation (% Crtl), a Osteoblasts, a None
Proliferation (% Crtl), a Osteoblasts, b FTY720
Proliferation (% Crtl), a Osteoblasts, c A83-01
Proliferation (% Crtl), a Osteoblasts, d K02288
Proliferation (% Crtl), a Osteoblasts, e M5939
Proliferation (% Crtl), a Osteoblasts, f  Odanacatic
Proliferation (% Crtl), a Osteoblasts, g Carf ilzomib
Proliferation (% Crtl), a Osteoblasts, h Phloretin
Proliferation (% Crtl), a Osteoblasts, i Decitabine
Proliferation (% Crtl), a Osteoblasts, j Amiloride
Proliferation (% Crtl), a Osteoblasts, k Osteoprotegerin
Proliferation (% Crtl), a Osteoblasts, l Tacrolimus
Proliferation (% Crtl), a Osteoblasts, m Carbozantnib
Proliferation (% Crtl), a Osteoblasts, n GM6001
Proliferation (% Crtl), a Osteoblasts, o Cathepsin inhibitor
Proliferation (% Crtl), a Osteoblasts, p Osteostatin
Proliferation (% Crtl), b Osteoclasts, a None
Proliferation (% Crtl), b Osteoclasts, b FTY720
Proliferation (% Crtl), b Osteoclasts, c A83-01
Proliferation (% Crtl), b Osteoclasts, d K02288
Proliferation (% Crtl), b Osteoclasts, e M5939
Proliferation (% Crtl), b Osteoclasts, f  Odanacatic
Proliferation (% Crtl), b Osteoclasts, g Carf ilzomib
Proliferation (% Crtl), b Osteoclasts, h Phloretin
Proliferation (% Crtl), b Osteoclasts, i Decitabine
Proliferation (% Crtl), b Osteoclasts, j Amiloride
Proliferation (% Crtl), b Osteoclasts, k Osteoprotegerin
Proliferation (% Crtl), b Osteoclasts, l Tacrolimus
Proliferation (% Crtl), b Osteoclasts, m Carbozantnib
Proliferation (% Crtl), b Osteoclasts, n GM6001
Proliferation (% Crtl), b Osteoclasts, o Cathepsin inhibitor
Proliferation (% Crtl), b Osteoclasts, p Osteostatin
Results for totals may not agree w ith results for individual cells because of missing values for split variables.
Descriptive Statistics
Split By: Cell Type, Inhibitor
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Figure 308.  Osteoblast and Osteoclast proliferation in response to growth factors 




3 489130.678 163043.559 2.370 .0706 7.111 .584
300 20634934.504 68783.115
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioactive molecule
Residual
ANOVA Table for Proliferation (% Crtl)
15 7699872.001 513324.800 11.013 <.0001 165.192 1.000
288 13424193.181 46611.782
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor
Residual
ANOVA Table for Proliferation (% Crtl)
1 2922343.263 2922343.263 48.487 <.0001 48.487 1.000
302 18201721.919 60270.602
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Cell Type
Residual









186.103 264.039 15.144 304 14.791 968.523 311
99.972 113.353 40.076 8 25.818 299.345 8
144.680 91.675 32.412 8 88.255 363.636 8
36.563 19.086 6.748 8 20.755 79.691 8
38.347 11.135 3.937 8 22.373 52.182 8
28.228 3.517 1.243 8 24.300 34.582 8
50.385 46.844 16.562 8 26.927 164.027 8
81.200 71.809 25.388 8 31.682 247.027 8
332.065 44.262 15.649 8 264.264 363.636 8
57.419 38.360 13.562 8 20.336 133.836 8
265.192 101.713 35.961 8 94.045 363.636 8
77.855 93.063 32.903 8 18.636 250.236 8
44.949 69.869 24.702 8 14.855 217.718 8
26.866 11.663 4.124 8 16.236 54.591 8
25.800 6.110 2.160 8 14.791 33.391 8
51.669 39.492 13.962 8 26.436 147.464 8
74.950 41.397 14.636 8 43.836 156.200 8
102.906 118.665 41.954 8 23.945 363.636 8
81.980 98.925 34.975 8 23.664 283.327 8
52.066 39.258 13.880 8 22.791 144.809 8
100.000 15.756 5.571 8 72.881 119.855 8
567.887 343.902 121.588 8 231.961 968.523 8
68.674 61.180 21.630 8 32.446 211.380 8
112.863 136.643 48.311 8 37.530 434.140 8
233.111 294.620 104.164 8 44.068 808.232 8
359.746 421.794 149.127 8 47.458 968.523 8
373.184 402.446 142.286 8 50.605 968.523 8
511.047 249.486 88.207 8 289.104 968.523 8
877.633 129.986 45.957 8 654.964 968.523 8
968.523 0.000 0.000 8 968.523 968.523 8
66.840 6.115 2.162 8 58.620 76.247 8
54.528 9.222 3.260 8 38.935 70.508 8
323.735 274.084 96.904 8 150.073 844.988 8
64.495 14.146 5.001 8 51.404 88.765 8
315.763 256.472 90.676 8 145.448 839.709 8
69.655 19.005 6.719 8 38.450 92.760 8
131.749 25.079 8.867 8 106.295 172.639 8
92.100 79.688 28.174 8 38.741 257.385 8
107.294 151.321 53.500 8 37.772 477.240 8
Mean Std. Dev. Std. Error Count Minimum Maximum # Missing
Proliferation (% Crtl), Total
Proliferation (% Crtl), a Osteoblasts, a None, a None
Proliferation (% Crtl), a Osteoblasts, a None, b FTY720
Proliferation (% Crtl), a Osteoblasts, a None, c A83-01
Proliferation (% Crtl), a Osteoblasts, a None, d K02288
Proliferation (% Crtl), a Osteoblasts, a None, e M5939
Proliferation (% Crtl), a Osteoblasts, a None, f Odanacatic
Proliferation (% Crtl), a Osteoblasts, a None, g Carfilzomib
Proliferation (% Crtl), a Osteoblasts, a None, h Phloretin
Proliferation (% Crtl), a Osteoblasts, a None, i Decitabine
Proliferation (% Crtl), a Osteoblasts, a None, j Amiloride
Proliferation (% Crtl), a Osteoblasts, a None, k Osteoprotegerin
Proliferation (% Crtl), a Osteoblasts, a None, l Tacrolimus
Proliferation (% Crtl), a Osteoblasts, a None, m Carbozantnib
Proliferation (% Crtl), a Osteoblasts, a None, n GM6001
Proliferation (% Crtl), a Osteoblasts, a None, o Cathepsin inhibitor
Proliferation (% Crtl), a Osteoblasts, a None, p Osteostatin
Proliferation (% Crtl), a Osteoblasts, b S1P, a None
Proliferation (% Crtl), a Osteoblasts, c TGF-B1, a None
Proliferation (% Crtl), a Osteoblasts, d BMP2, a None
Proliferation (% Crtl), b Osteoclasts, a None, a None
Proliferation (% Crtl), b Osteoclasts, a None, b FTY720
Proliferation (% Crtl), b Osteoclasts, a None, c A83-01
Proliferation (% Crtl), b Osteoclasts, a None, d K02288
Proliferation (% Crtl), b Osteoclasts, a None, e M5939
Proliferation (% Crtl), b Osteoclasts, a None, f Odanacatic
Proliferation (% Crtl), b Osteoclasts, a None, g Carfilzomib
Proliferation (% Crtl), b Osteoclasts, a None, h Phloretin
Proliferation (% Crtl), b Osteoclasts, a None, i Decitabine
Proliferation (% Crtl), b Osteoclasts, a None, j Amiloride
Proliferation (% Crtl), b Osteoclasts, a None, k Osteoprotegerin
Proliferation (% Crtl), b Osteoclasts, a None, l Tacrolimus
Proliferation (% Crtl), b Osteoclasts, a None, m Carbozantnib
Proliferation (% Crtl), b Osteoclasts, a None, n GM6001
Proliferation (% Crtl), b Osteoclasts, a None, o Cathepsin inhibitor
Proliferation (% Crtl), b Osteoclasts, a None, p Osteostatin
Proliferation (% Crtl), b Osteoclasts, b S1P, a None
Proliferation (% Crtl), b Osteoclasts, c TGF-B1, a None
Proliferation (% Crtl), b Osteoclasts, d BMP2, a None
Results for totals may not agree w ith results for individual cells because of missing values for split variables.
Descriptive Statistics
Split By: Cell Type, Bioactive molecule, Inhibitor
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1 22798.162 22798.162 7.004 .0090 7.004 .757
150 488278.332 3255.189
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioactive mol. ? (YN)
Residual
ANOVA Table for Mineralization (Osteoblasts % of contol)
24 67.651 101.930 20.806
128 34.065 44.307 3.916
Count Mean Std. Dev. Std. Err.
a Yes
b No
Means Table for Mineralization (Osteoblasts % of contol)
Effect: Bioactive mol. ? (YN)
1 53622.926 53622.926 17.583 <.0001 17.583 .994
150 457453.568 3049.690
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor? (YN)
Residual
ANOVA Table for Mineralization (Osteoblasts % of contol)
120 29.669 40.857 3.730
32 75.740 91.371 16.152
Count Mean Std. Dev. Std. Err.
a Yes
b No
Means Table for Mineralization (Osteoblasts % of contol)
Effect: Inhibitor? (YN)
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A singularity w as encountered w hile sw eeping SSCP matrix.
There may be too many missing cells or the covariates or
dependents may be correlated.
ANOVA Table for Mineralization (Osteoblasts % of contol)
Split By: Bioactive mol. ? (YN)
Cell: a Yes
1 37106.273 37106.273 22.032 <.0001 22.032 .999
126 212208.711 1684.196
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor? (YN)
Residual
ANOVA Table for Mineralization (Osteoblasts % of contol)
Split By: Bioactive mol. ? (YN)
Cell: b No
39.368 58.177 4.719 152 8.201 292.835 463
29.669 40.857 3.730 120 8.201 200.446 360
67.651 101.930 20.806 24 9.482 292.835 72
100.007 44.019 15.563 8 13.353 141.410 24
Mean Std. Dev. Std. Error Count Minimum Maximum # Missing
Mineralization (Osteoblasts % of contol), Total
Mineralization (Osteoblasts % of contol), a Yes, b No
Mineralization (Osteoblasts % of contol), b No, a Yes
Mineralization (Osteoblasts % of contol), b No, b No
Results for totals may not agree w ith results for individual cells because of missing values for split variables.
Descriptive Statistics
Split By: Inhibitor? (YN), Bioactive mol. ? (YN)
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Figure 312.  Osteoblast mineralization in response to individual growth factors. 
 
 




3 86320.322 28773.441 10.026 <.0001 30.077 .999
148 424756.172 2869.974
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioactive molecule
Residual
ANOVA Table for Mineralization (Osteoblasts % of contol)
128 34.065 44.307 3.916
8 139.074 133.270 47.118
8 43.950 81.814 28.926
8 19.930 24.667 8.721





Means Table for Mineralization (Osteoblasts % of contol)
Effect: Bioactive molecule
15 194626.686 12975.112 5.576 <.0001 83.644 1.000
136 316449.808 2326.837
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor
Residual
ANOVA Table for Mineralization (Osteoblasts % of contol)
32 75.740 91.371 16.152
8 76.248 34.292 12.124
8 48.610 66.930 23.663
8 11.835 1.467 .519
8 12.975 1.900 .672
8 13.755 2.041 .722
8 11.032 1.548 .547
8 138.094 45.502 16.087
8 10.664 1.498 .530
8 22.112 6.986 2.470
8 10.781 1.659 .586
8 14.799 4.828 1.707
8 40.615 19.756 6.985
8 11.991 5.153 1.822
8 10.374 .591 .209
8 11.147 1.347 .476


































1 156240.933 156240.933 9.340 .0027 9.340 .877
150 2509237.074 16728.247
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor? (YN)
Residual
ANOVA Table for Collagen degradation (Osteoclasts % Crtl)
120 190.978 144.996 13.236
32 112.336 15.444 2.730
Count Mean Std. Dev. Std. Err.
a Yes
b No
Means Table for Collagen degradation (Osteoclasts % Crtl)
Effect: Inhibitor? (YN)
1 95751.904 95751.904 5.589 .0194 5.589 .649
150 2569726.103 17131.507
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioactive mol. ? (YN)
Residual
ANOVA Table for Collagen degradation (Osteoclasts % Crtl)
24 116.458 14.979 3.058
128 185.289 142.104 12.560
Count Mean Std. Dev. Std. Err.
a Yes
b No
Means Table for Collagen degradation (Osteoclasts % Crtl)
Effect: Bioactive mol. ? (YN)
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15 2061555.689 137437.046 30.950 <.0001 464.251 1.000
136 603922.318 4440.605
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Inhibitor
Residual
ANOVA Table for Collagen degradation (Osteoclasts % Crtl)
32 112.336 15.444 2.730
8 568.702 178.286 63.034
8 136.234 14.853 5.251
8 130.913 25.003 8.840
8 118.862 4.668 1.650
8 125.962 28.156 9.955
8 371.186 172.559 61.009
8 273.189 119.073 42.099
8 88.958 7.572 2.677
8 271.731 67.073 23.714
8 107.869 10.976 3.881
8 138.942 23.960 8.471
8 130.737 33.205 11.740
8 136.554 14.023 4.958
8 143.093 33.902 11.986
8 121.731 10.859 3.839

















Means Table for Collagen degradation (Osteoclasts % Crtl)
Effect: Inhibitor
3 95863.915 31954.638 1.840 .1423 5.521 .460
148 2569614.092 17362.257
DF Sum of Squares Mean Square F-Value P-Value Lambda Pow er
Bioactive molecule
Residual
ANOVA Table for Collagen degradation (Osteoclasts % Crtl)
128 185.289 142.104 12.560
8 116.106 20.722 7.326
8 119.263 14.775 5.224
8 114.006 8.578 3.033





Means Table for Collagen degradation (Osteoclasts % Crtl)
Effect: Bioactive molecule
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Figure 318. Raw data used for the statistical analysis of the Migration of Osteoblasts 
 
 and Osteoclasts. 
 
Group #  Assay type   Migrated cells Cell Type  Bioactive inhibitor     Bioactive molecule Inhibitor? (Y/N)         
1.1  Transwell migration  0 Osteoblasts none   a None   No 
1.2  Transwell migration  0 Osteoblasts none   a None   No 
1.3  Transwell migration  0 Osteoblasts none   a None   No 
1.4  Transwell migration  0 Osteoblasts none   a None   No 
1.5  Transwell migration  0 Osteoblasts none   a None   No 
1.6  Transwell migration  0 Osteoblasts none   a None   No 
1.7  Transwell migration  0 Osteoblasts none   a None   No 
1.8  Transwell migration  0 Osteoblasts none   a None   No 
1.9  Transwell migration  0 Osteoblasts none   a None   No 
1.1  Transwell migration  0 Osteoblasts none   a None   No 
1.11  Transwell migration  1 Osteoblasts none   a None   No 
1.12  Transwell migration  0 Osteoblasts none   a None   No 
1.13  Transwell migration  0 Osteoblasts none   a None   No 
1.14  Transwell migration  0 Osteoblasts none   a None   No 
1.15  Transwell migration  0 Osteoblasts none   a None   No 
1.16  Transwell migration  0 Osteoblasts none   a None   No 
1.17  Transwell migration  0 Osteoblasts none   a None   No 
1.18  Transwell migration  0 Osteoblasts none   a None   No 
2.1  Transwell migration  0 Osteoclasts none   a None   No 
2.2  Transwell migration  0 Osteoclasts none   a None   No 
2.3  Transwell migration  0 Osteoclasts none   a None   No 
2.4  Transwell migration  0 Osteoclasts none   a None   No 
2.5  Transwell migration  0 Osteoclasts none   a None   No 
2.6  Transwell migration  0 Osteoclasts none   a None   No 
2.7  Transwell migration  0 Osteoclasts none   a None   No 
2.8  Transwell migration  0 Osteoclasts none   a None   No 
2.9  Transwell migration  0 Osteoclasts none   a None   No 
2.1  Transwell migration  0 Osteoclasts none   a None   No 
2.11  Transwell migration  0 Osteoclasts none   a None   No 
2.12  Transwell migration  1 Osteoclasts none   a None   No 
2.13  Transwell migration  0 Osteoclasts none   a None   No 
2.14  Transwell migration  0 Osteoclasts none   a None   No 
2.15  Transwell migration  0 Osteoclasts none   a None   No 
2.16  Transwell migration  1 Osteoclasts none   a None   No 
2.17  Transwell migration  0 Osteoclasts none   a None   No 
2.18  Transwell migration  0 Osteoclasts none   a None   No 
3.1  Transwell migration  4 Osteoblasts none   d S1P   No 
3.2  Transwell migration  3 Osteoblasts none   d S1P   No 
3.3  Transwell migration  1 Osteoblasts none   d S1P   No 
3.4  Transwell migration  3 Osteoblasts none   d S1P   No 
3.5  Transwell migration  5 Osteoblasts none   d S1P   No 
3.6  Transwell migration  3 Osteoblasts none   d S1P   No 
3.7  Transwell migration  0 Osteoblasts none   d S1P   No 
3.8  Transwell migration  1 Osteoblasts none   d S1P   No 
3.9  Transwell migration  2 Osteoblasts none   d S1P   No 
3.1  Transwell migration  4 Osteoblasts none   d S1P   No 
3.11  Transwell migration  4 Osteoblasts none   d S1P   No 
3.12  Transwell migration  1 Osteoblasts none   d S1P   No 
3.13  Transwell migration  5 Osteoblasts none   d S1P   No 
3.14  Transwell migration  4 Osteoblasts none   d S1P   No 
3.15  Transwell migration  3 Osteoblasts none   d S1P   No 
3.16  Transwell migration  6 Osteoblasts none   d S1P   No 
3.17  Transwell migration  6 Osteoblasts none   d S1P   No 
3.18  Transwell migration  3 Osteoblasts none   d S1P   No 
4.1  Transwell migration  1 Osteoclasts none   d S1P   No 
4.2  Transwell migration  5 Osteoclasts none   d S1P   No 
4.3  Transwell migration  3 Osteoclasts none   d S1P   No 
4.4  Transwell migration  0 Osteoclasts none   d S1P   No 
4.5  Transwell migration  0 Osteoclasts none   d S1P   No 
4.6  Transwell migration  0 Osteoclasts none   d S1P   No 
4.7  Transwell migration  0 Osteoclasts none   d S1P   No 
4.8  Transwell migration  0 Osteoclasts none   d S1P   No 
4.9  Transwell migration  2 Osteoclasts none   d S1P   No 
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Group #  Assay type   Migrated cells Cell Type  Bioactive inhibitor     Bioactive molecule Inhibitor? (Y/N)  
4.1  Transwell migration  2 Osteoclasts none   d S1P   No 
4.11  Transwell migration  3 Osteoclasts none   d S1P   No 
4.12  Transwell migration  1 Osteoclasts none   d S1P   No 
4.13  Transwell migration  0 Osteoclasts none   d S1P   No 
4.14  Transwell migration  3 Osteoclasts none   d S1P   No 
4.15  Transwell migration  2 Osteoclasts none   d S1P   No 
4.16  Transwell migration  5 Osteoclasts none   d S1P   No 
4.17  Transwell migration  8 Osteoclasts none   d S1P   No 
4.18  Transwell migration  2 Osteoclasts none   d S1P   No 
5.1  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.2  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.3  Transwell migration  2 Osteoblasts FTY720   d S1P   Yes 
5.4  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.5  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.6  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.7  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.8  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.9  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.1  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.11  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.12  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.13  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.14  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.15  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.16  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.17  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
5.18  Transwell migration  0 Osteoblasts FTY720   d S1P   Yes 
6.1  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.2  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.3  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.4  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.5  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.6  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.7  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.8  Transwell migration  1 Osteoclasts FTY720   d S1P   Yes 
6.9  Transwell migration  1 Osteoclasts FTY720   d S1P   Yes 
6.1  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.11  Transwell migration  1 Osteoclasts FTY720   d S1P   Yes 
6.12  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.13  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.14  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.15  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.16  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.17  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
6.18  Transwell migration  0 Osteoclasts FTY720   d S1P   Yes 
7.1  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.2  Transwell migration  1 Osteoblasts none   c TGF-B   No 
7.3  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.4  Transwell migration  3 Osteoblasts none   c TGF-B   No 
7.5  Transwell migration  1 Osteoblasts none   c TGF-B   No 
7.6  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.7  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.8  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.9  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.1  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.11  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.12  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.13  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.14  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.15  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.16  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.17  Transwell migration  0 Osteoblasts none   c TGF-B   No 
7.18  Transwell migration  0 Osteoblasts none   c TGF-B   No 
8.1  Transwell migration  1 Osteoclasts none   c TGF-B   No 
8.2  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.3  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.4  Transwell migration  3 Osteoclasts none   c TGF-B   No 
8.5  Transwell migration  3 Osteoclasts none   c TGF-B   No 
8.6  Transwell migration  2 Osteoclasts none   c TGF-B   No 
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Group #  Assay type   Migrated cells Cell Type  Bioactive inhibitor     Bioactive molecule Inhibitor? (Y/N)  
8.7  Transwell migration  1 Osteoclasts none   c TGF-B   No 
8.8  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.9  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.1  Transwell migration  2 Osteoclasts none   c TGF-B   No 
8.11  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.12  Transwell migration  1 Osteoclasts none   c TGF-B   No 
8.13  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.14  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.15  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.16  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.17  Transwell migration  0 Osteoclasts none   c TGF-B   No 
8.18  Transwell migration  0 Osteoclasts none   c TGF-B   No 
9.1  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.2  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.3  Transwell migration  4 Osteoblasts A83-01   c TGF-B   Yes 
9.4  Transwell migration  1 Osteoblasts A83-01   c TGF-B   Yes 
9.5  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.6  Transwell migration  5 Osteoblasts A83-01   c TGF-B   Yes 
9.7  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.8  Transwell migration  1 Osteoblasts A83-01   c TGF-B   Yes 
9.9  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.1  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.11  Transwell migration  1 Osteoblasts A83-01   c TGF-B   Yes 
9.12  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.13  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.14  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.15  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.16  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
9.17  Transwell migration  1 Osteoblasts A83-01   c TGF-B   Yes 
9.18  Transwell migration  0 Osteoblasts A83-01   c TGF-B   Yes 
10.1  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.2  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.3  Transwell migration  1 Osteoclasts A83-01   c TGF-B   Yes 
10.4  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.5  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.6  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.7  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.8  Transwell migration  1 Osteoclasts A83-01   c TGF-B   Yes 
10.9  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.1  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.11  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.12  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.13  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.14  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.15  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.16  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.17  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
10.18  Transwell migration  0 Osteoclasts A83-01   c TGF-B   Yes 
11.1  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.2  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.3  Transwell migration  2 Osteoblasts none   b BMP2   No 
11.4  Transwell migration  1 Osteoblasts none   b BMP2   No 
11.5  Transwell migration  1 Osteoblasts none   b BMP2   No 
11.6  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.7  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.8  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.9  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.1  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.11  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.12  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.13  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.14  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.15  Transwell migration  1 Osteoblasts none   b BMP2   No 
11.16  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.17  Transwell migration  0 Osteoblasts none   b BMP2   No 
11.18  Transwell migration  0 Osteoblasts none   b BMP2   No 
12.1  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.2  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.3  Transwell migration  0 Osteoclasts none   b BMP2   No 
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Group #  Assay type   Migrated cells Cell Type  Bioactive inhibitor     Bioactive molecule Inhibitor? (Y/N)  
12.4  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.5  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.6  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.7  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.8  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.9  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.1  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.11  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.12  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.13  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.14  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.15  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.16  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.17  Transwell migration  0 Osteoclasts none   b BMP2   No 
12.18  Transwell migration  0 Osteoclasts none   b BMP2   No 
13.1  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.2  Transwell migration  1 Osteoblasts K02288   b BMP2   Yes 
13.3  Transwell migration  1 Osteoblasts K02288   b BMP2   Yes 
13.4  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.5  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.6  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.7  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.8  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.9  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.1  Transwell migration  3 Osteoblasts K02288   b BMP2   Yes 
13.11  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.12  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.13  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.14  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.15  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.16  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.17  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
13.18  Transwell migration  0 Osteoblasts K02288   b BMP2   Yes 
14.1  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.2  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.3  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.4  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.5  Transwell migration  1 Osteoclasts K02288   b BMP2   Yes 
14.6  Transwell migration  1 Osteoclasts K02288   b BMP2   Yes 
14.7  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.8  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.9  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.1  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.11  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.12  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.13  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.14  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.15  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.16  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.17  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
14.18  Transwell migration  0 Osteoclasts K02288   b BMP2   Yes 
15.1  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.2  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.3  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.4  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.5  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.6  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.7  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.8  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.9  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.1  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.11  Transwell migration  1 Osteoblasts Sclerostin   b BMP2   Yes 
15.12  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.13  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.14  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.15  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.16  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.17  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
15.18  Transwell migration  0 Osteoblasts Sclerostin   b BMP2   Yes 
 301
Group #  Assay type   Migrated cells Cell Type  Bioactive inhibitor     Bioactive molecule Inhibitor? (Y/N)  
16.1  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.2  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.3  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.4  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.5  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.6  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.7  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.8  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.9  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.1  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.11  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.12  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.13  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.14  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 
16.15  Transwell migration  0 Osteoclasts Sclerostin   b BMP2   Yes 








Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor Mineralization        Inhibitor?   Bioactive mol.? 
#          (Osteoblasts % crtl)      (YN) (YN) 
17 0.9729 a Bone mineralization a Osteoblasts a None  a None  139.986  b No b No 
17 0.0928 a Bone mineralization a Osteoblasts a None  a None  13.353  b No b No 
17 0.8652 a Bone mineralization a Osteoblasts a None  a None  124.489  b No b No 
17 0.9828 a Bone mineralization a Osteoblasts a None  a None  141.410  b No b No 
17 0.5515 a Bone mineralization a Osteoblasts a None  a None  79.353  b No b No 
17 0.6048 a Bone mineralization a Osteoblasts a None  a None  87.022  b No b No 
17 0.9319 a Bone mineralization a Osteoblasts a None  a None  134.086  b No b No 
17 0.5585 a Bone mineralization a Osteoblasts a None  a None  80.360  b No b No 
19 0.0659 a Bone mineralization a Osteoblasts b S1P  a None  9.482  b No a Yes 
19 0.0871 a Bone mineralization a Osteoblasts b S1P  a None  12.532  b No a Yes 
19 0.0837 a Bone mineralization a Osteoblasts b S1P  a None  12.043  b No a Yes 
19 0.3514 a Bone mineralization a Osteoblasts b S1P  a None  50.561  b No a Yes 
19 1.9586 a Bone mineralization a Osteoblasts b S1P  a None  281.813  b No a Yes 
19 2.0200 a Bone mineralization a Osteoblasts b S1P  a None  290.647  b No a Yes 
19 2.0352 a Bone mineralization a Osteoblasts b S1P  a None  292.835  b No a Yes 
19 1.1306 a Bone mineralization a Osteoblasts b S1P  a None  162.676  b No a Yes 
21 1.0451 a Bone mineralization a Osteoblasts a None  b FTY720  150.374  a Yes b No 
21 0.6030 a Bone mineralization a Osteoblasts a None  b FTY720  86.763  a Yes b No 
21 0.4525 a Bone mineralization a Osteoblasts a None  b FTY720  65.108  a Yes b No 
21 0.4478 a Bone mineralization a Osteoblasts a None  b FTY720  64.432  a Yes b No 
21 0.4873 a Bone mineralization a Osteoblasts a None  b FTY720  70.115  a Yes b No 
21 0.2486 a Bone mineralization a Osteoblasts a None  b FTY720  35.770  a Yes b No 
21 0.5952 a Bone mineralization a Osteoblasts a None  b FTY720  85.640  a Yes b No 
21 0.3599 a Bone mineralization a Osteoblasts a None  b FTY720  51.784  a Yes b No 
23 0.0695 a Bone mineralization a Osteoblasts c TGF-B1  a None  10.000  b No a Yes 
23 0.0843 a Bone mineralization a Osteoblasts c TGF-B1  a None  12.129  b No a Yes 
23 0.0718 a Bone mineralization a Osteoblasts c TGF-B1  a None  10.331  b No a Yes 
23 0.1504 a Bone mineralization a Osteoblasts c TGF-B1  a None  21.640  b No a Yes 
23 0.0823 a Bone mineralization a Osteoblasts c TGF-B1  a None  11.842  b No a Yes 
23 0.0829 a Bone mineralization a Osteoblasts c TGF-B1  a None  11.928  b No a Yes 
23 1.7084 a Bone mineralization a Osteoblasts c TGF-B1  a None  245.813  b No a Yes 
23 0.1940 a Bone mineralization a Osteoblasts c TGF-B1  a None  27.914  b No a Yes 
25 0.0941 a Bone mineralization a Osteoblasts a None  c A83-01  13.540  a Yes b No 
25 0.0981 a Bone mineralization a Osteoblasts a None  c A83-01  14.115  a Yes b No 
25 0.1034 a Bone mineralization a Osteoblasts a None  c A83-01  14.878  a Yes b No 
25 0.1492 a Bone mineralization a Osteoblasts a None  c A83-01  21.468  a Yes b No 
25 0.0842 a Bone mineralization a Osteoblasts a None  c A83-01  12.115  a Yes b No 
25 0.1028 a Bone mineralization a Osteoblasts a None  c A83-01  14.791  a Yes b No 
25 1.3628 a Bone mineralization a Osteoblasts a None  c A83-01  196.086  a Yes b No 
25 0.7081 a Bone mineralization a Osteoblasts a None  c A83-01  101.885  a Yes b No 
27 0.0687 a Bone mineralization a Osteoblasts d BMP2  a None  9.885  b No a Yes 
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27 0.0826 a Bone mineralization a Osteoblasts d BMP2  a None  11.885  b No a Yes 
27 0.0851 a Bone mineralization a Osteoblasts d BMP2  a None  12.245  b No a Yes 
27 0.0689 a Bone mineralization a Osteoblasts d BMP2  a None  9.914  b No a Yes 
27 0.0885 a Bone mineralization a Osteoblasts d BMP2  a None  12.734  b No a Yes 
27 0.0680 a Bone mineralization a Osteoblasts d BMP2  a None  9.784  b No a Yes 
27 0.0840 a Bone mineralization a Osteoblasts d BMP2  a None  12.086  b No a Yes 
27 0.5623 a Bone mineralization a Osteoblasts d BMP2  a None  80.906  b No a Yes 
29 0.0899 a Bone mineralization a Osteoblasts a None  d K02288  12.935  a Yes b No 
29 0.0783 a Bone mineralization a Osteoblasts a None  d K02288  11.266  a Yes b No 
29 0.0831 a Bone mineralization a Osteoblasts a None  d K02288  11.957  a Yes b No 
29 0.0722 a Bone mineralization a Osteoblasts a None  d K02288  10.388  a Yes b No 
29 0.0907 a Bone mineralization a Osteoblasts a None  d K02288  13.050  a Yes b No 
29 0.0719 a Bone mineralization a Osteoblasts a None  d K02288  10.345  a Yes b No 
29 0.0728 a Bone mineralization a Osteoblasts a None  d K02288  10.475  a Yes b No 
29 0.0991 a Bone mineralization a Osteoblasts a None  d K02288  14.259  a Yes b No 
31 0.0707 a Bone mineralization a Osteoblasts a None  e M5939  10.173  a Yes b No 
31 0.0872 a Bone mineralization a Osteoblasts a None  e M5939  12.547  a Yes b No 
31 0.0947 a Bone mineralization a Osteoblasts a None  e M5939  13.626  a Yes b No 
31 0.0882 a Bone mineralization a Osteoblasts a None  e M5939  12.691  a Yes b No 
31 0.0917 a Bone mineralization a Osteoblasts a None  e M5939  13.194  a Yes b No 
31 0.0853 a Bone mineralization a Osteoblasts a None  e M5939  12.273  a Yes b No 
31 0.0858 a Bone mineralization a Osteoblasts a None  e M5939  12.345  a Yes b No 
31 0.1178 a Bone mineralization a Osteoblasts a None  e M5939  16.950  a Yes b No 
33 0.0849 a Bone mineralization a Osteoblasts a None  f Odanacatic 12.216  a Yes b No 
33 0.1173 a Bone mineralization a Osteoblasts a None  f Odanacatic 16.878  a Yes b No 
33 0.0753 a Bone mineralization a Osteoblasts a None  f Odanacatic 10.835  a Yes b No 
33 0.0827 a Bone mineralization a Osteoblasts a None  f Odanacatic 11.899  a Yes b No 
33 0.1105 a Bone mineralization a Osteoblasts a None  f Odanacatic 15.899  a Yes b No 
33 0.0970 a Bone mineralization a Osteoblasts a None  f Odanacatic 13.957  a Yes b No 
33 0.0973 a Bone mineralization a Osteoblasts a None  f Odanacatic 14.000  a Yes b No 
33 0.0998 a Bone mineralization a Osteoblasts a None  f Odanacatic 14.360  a Yes b No 
35 0.0651 a Bone mineralization a Osteoblasts a None  g Carfilzomib 9.367  a Yes b No 
35 0.0738 a Bone mineralization a Osteoblasts a None  g Carfilzomib 10.619  a Yes b No 
35 0.0858 a Bone mineralization a Osteoblasts a None  g Carfilzomib 12.345  a Yes b No 
35 0.0813 a Bone mineralization a Osteoblasts a None  g Carfilzomib 11.698  a Yes b No 
35 0.0760 a Bone mineralization a Osteoblasts a None  g Carfilzomib 10.935  a Yes b No 
35 0.0806 a Bone mineralization a Osteoblasts a None  g Carfilzomib 11.597  a Yes b No 
35 0.0919 a Bone mineralization a Osteoblasts a None  g Carfilzomib 13.223  a Yes b No 
35 0.0589 a Bone mineralization a Osteoblasts a None  g Carfilzomib 8.475  a Yes b No 
37 1.3357 a Bone mineralization a Osteoblasts a None  h Phloretin 192.187  a Yes b No 
37 0.9142 a Bone mineralization a Osteoblasts a None  h Phloretin 131.540  a Yes b No 
37 1.3931 a Bone mineralization a Osteoblasts a None  h Phloretin 200.446  a Yes b No 
37 0.9039 a Bone mineralization a Osteoblasts a None  h Phloretin 130.058  a Yes b No 
37 1.1578 a Bone mineralization a Osteoblasts a None  h Phloretin 166.590  a Yes b No 
37 0.8168 a Bone mineralization a Osteoblasts a None  h Phloretin 117.525  a Yes b No 
37 0.4917 a Bone mineralization a Osteoblasts a None  h Phloretin 70.748  a Yes b No 
37 0.6648 a Bone mineralization a Osteoblasts a None  h Phloretin 95.655  a Yes b No 
39 0.0692 a Bone mineralization a Osteoblasts a None  i Decitabine 9.957  a Yes b No 
39 0.0634 a Bone mineralization a Osteoblasts a None  i Decitabine 9.122  a Yes b No 
39 0.0741 a Bone mineralization a Osteoblasts a None  i Decitabine 10.662  a Yes b No 
39 0.0740 a Bone mineralization a Osteoblasts a None  i Decitabine 10.647  a Yes b No 
39 0.0817 a Bone mineralization a Osteoblasts a None  i Decitabine 11.755  a Yes b No 
39 0.0718 a Bone mineralization a Osteoblasts a None  i Decitabine 10.331  a Yes b No 
39 0.0635 a Bone mineralization a Osteoblasts a None  i Decitabine 9.137  a Yes b No 
39 0.0952 a Bone mineralization a Osteoblasts a None  i Decitabine 13.698  a Yes b No  
41 0.1038 a Bone mineralization a Osteoblasts a None  j Amiloride 14.935  a Yes b No 
41 0.1394 a Bone mineralization a Osteoblasts a None  j Amiloride 20.058  a Yes b No 
41 0.2182 a Bone mineralization a Osteoblasts a None  j Amiloride 31.396  a Yes b No 
41 0.2126 a Bone mineralization a Osteoblasts a None  j Amiloride 30.590  a Yes b No 
41 0.1210 a Bone mineralization a Osteoblasts a None  j Amiloride 17.410  a Yes b No 
41 0.1485 a Bone mineralization a Osteoblasts a None  j Amiloride 21.367  a Yes b No 
41 0.1922 a Bone mineralization a Osteoblasts a None  j Amiloride 27.655  a Yes b No 
41 0.0937 a Bone mineralization a Osteoblasts a None  j Amiloride 13.482  a Yes b No 
43 0.0602 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 8.662  a Yes b No 
43 0.0729 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 10.489  a Yes b No 
43 0.0733 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 10.547  a Yes b No 
43 0.0884 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 12.719  a Yes b No 
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43 0.0802 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 11.540  a Yes b No 
43 0.0870 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 12.518  a Yes b No 
43 0.0804 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 11.568  a Yes b No 
43 0.0570 a Bone mineralization a Osteoblasts a None  k Osteoprotegerin 8.201  a Yes b No 
45 0.0902 a Bone mineralization a Osteoblasts a None  l Tacrolimus 12.978  a Yes b No 
45 0.0681 a Bone mineralization a Osteoblasts a None  l Tacrolimus 9.799  a Yes b No 
45 0.1148 a Bone mineralization a Osteoblasts a None  l Tacrolimus 16.518  a Yes b No 
45 0.0855 a Bone mineralization a Osteoblasts a None  l Tacrolimus 12.302  a Yes b No 
45 0.1072 a Bone mineralization a Osteoblasts a None  l Tacrolimus 15.424  a Yes b No 
45 0.1534 a Bone mineralization a Osteoblasts a None  l Tacrolimus 22.072  a Yes b No 
45 0.1436 a Bone mineralization a Osteoblasts a None  l Tacrolimus 20.662  a Yes b No 
45 0.0600 a Bone mineralization a Osteoblasts a None  l Tacrolimus 8.633  a Yes b No 
47 0.1836 a Bone mineralization a Osteoblasts a None  m Carbozantnib 26.417  a Yes b No 
47 0.5463 a Bone mineralization a Osteoblasts a None  m Carbozantnib 78.604  a Yes b No 
47 0.2358 a Bone mineralization a Osteoblasts a None  m Carbozantnib 33.928  a Yes b No 
47 0.4289 a Bone mineralization a Osteoblasts a None  m Carbozantnib 61.712  a Yes b No 
47 0.2182 a Bone mineralization a Osteoblasts a None  m Carbozantnib 31.396  a Yes b No 
47 0.2533 a Bone mineralization a Osteoblasts a None  m Carbozantnib 36.446  a Yes b No 
47 0.2633 a Bone mineralization a Osteoblasts a None  m Carbozantnib 37.885  a Yes b No 
47 0.1288 a Bone mineralization a Osteoblasts a None  m Carbozantnib 18.532  a Yes b No 
49 0.0712 a Bone mineralization a Osteoblasts a None  n GM6001 10.245  a Yes b No 
49 0.0683 a Bone mineralization a Osteoblasts a None  n GM6001 9.827  a Yes b No 
49 0.0764 a Bone mineralization a Osteoblasts a None  n GM6001 10.993  a Yes b No 
49 0.0821 a Bone mineralization a Osteoblasts a None  n GM6001 11.813  a Yes b No 
49 0.0679 a Bone mineralization a Osteoblasts a None  n GM6001 9.770  a Yes b No 
49 0.0680 a Bone mineralization a Osteoblasts a None  n GM6001 9.784  a Yes b No 
49 0.1707 a Bone mineralization a Osteoblasts a None  n GM6001 24.561  a Yes b No 
49 0.0621 a Bone mineralization a Osteoblasts a None  n GM6001 8.935  a Yes b No 
51 0.0701 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor   10.086  a Yes b No 
51 0.0700 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor   10.072  a Yes b No 
51 0.0756 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor   10.878  a Yes b No 
51 0.0795 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor   11.439  a Yes b No 
51 0.0694 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor    9.986  a Yes b No 
51 0.0707 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor   10.173  a Yes b No 
51 0.0746 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor    10.734  a Yes b No 
51 0.0669 a Bone mineralization a Osteoblasts a None  o Cathepsin inhibitor     9.626  a Yes b No 
53 0.0748 a Bone mineralization a Osteoblasts a None  p Osteostatin      10.763 a Yes b No 
53 0.0833 a Bone mineralization a Osteoblasts a None  p Osteostatin      11.986 a Yes b No 
53 0.0790 a Bone mineralization a Osteoblasts a None  p Osteostatin      11.367 a Yes b No 
53 0.0758 a Bone mineralization a Osteoblasts a None  p Osteostatin      10.906 a Yes b No 
53 0.0788 a Bone mineralization a Osteoblasts a None  p Osteostatin      11.338 a Yes b No 
53 0.0769 a Bone mineralization a Osteoblasts a None  p Osteostatin      11.065 a Yes b No 
53 0.0923 a Bone mineralization a Osteoblasts a None  p Osteostatin       13.281 a Yes b No 
53 0.0589 a Bone mineralization a Osteoblasts a None  p Osteostatin       8.475  a Yes b No 
 
 
Figure 320.  Raw data used for the statistical analysis of the Collagen degradation by  
 
Osteoclasts  
    
Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor Collagen degrad.       Inhibitor?   Bioactive mol.? 
#          (Osteoclasts % crtl)      (YN) (YN) 
 
18 0.0803 b Collagen degradation b Osteoclasts a None  a None  102.949   b No b No 
18 0.0751 b Collagen degradation b Osteoclasts a None  a None    96.282                  b No b No 
18 0.0896 b Collagen degradation b Osteoclasts a None  a None  114.872   b No b No 
18 0.0815 b Collagen degradation b Osteoclasts a None  a None  104.487   b No b No 
18 0.0799 b Collagen degradation b Osteoclasts a None  a None  102.436   b No b No 
18 0.0771 b Collagen degradation b Osteoclasts a None  a None    98.846   b No b No 
18 0.0639 b Collagen degradation b Osteoclasts a None  a None    81.923   b No b No 
18 0.0764 b Collagen degradation b Osteoclasts a None  a None    97.949   b No b No 
20 0.0708 b Collagen degradation b Osteoclasts b S1P  a None    90.769   b No a Yes 
20 0.0949 b Collagen degradation b Osteoclasts b S1P  a None    121.667  b No a Yes 
20 0.0879 b Collagen degradation b Osteoclasts b S1P  a None    112.692  b No a Yes 
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20 0.0884 b Collagen degradation b Osteoclasts b S1P  a None    113.333  b No a Yes 
20 0.0913 b Collagen degradation b Osteoclasts b S1P  a None    117.051  b No a Yes 
20 0.0939 b Collagen degradation b Osteoclasts b S1P  a None    120.385  b No a Yes 
20 0.1238 b Collagen degradation b Osteoclasts b S1P  a None    158.718  b No a Yes 
20 0.0735 b Collagen degradation b Osteoclasts b S1P  a None    94.231   b No a Yes 
22 0.5698 b Collagen degradation b Osteoclasts a None  b FTY720    730.513  a Yes b No 
22 0.6000 b Collagen degradation b Osteoclasts a None  b FTY720    769.231  a Yes b No 
22 0.3937 b Collagen degradation b Osteoclasts a None  b FTY720     504.744  a Yes b No 
22 0.4735 b Collagen degradation b Osteoclasts a None  b FTY720    607.051  a Yes b No 
22 0.5119 b Collagen degradation b Osteoclasts a None  b FTY720    656.282  a Yes b No 
22 0.4907 b Collagen degradation b Osteoclasts a None  b FTY720    629.103  a Yes b No 
22 0.3359 b Collagen degradation b Osteoclasts a None  b FTY720    430.641  a Yes b No 
22 0.1732 b Collagen degradation b Osteoclasts a None  b FTY720    222.051  a Yes b No 
24 0.0869 b Collagen degradation b Osteoclasts c TGF-B1  a None    111.410  b No a Yes 
24 0.0918 b Collagen degradation b Osteoclasts c TGF-B1  a None    117.692  b No a Yes 
24 0.1031 b Collagen degradation b Osteoclasts c TGF-B1  a None    132.179  b No a Yes 
24 0.0901 b Collagen degradation b Osteoclasts c TGF-B1  a None    115.513  b No a Yes 
24 0.0933 b Collagen degradation b Osteoclasts c TGF-B1  a None    119.615  b No a Yes 
24 0.1155 b Collagen degradation b Osteoclasts c TGF-B1  a None    148.077  b No a Yes 
24 0.0850 b Collagen degradation b Osteoclasts c TGF-B1  a None     108.974  b No a Yes 
24 0.0785 b Collagen degradation b Osteoclasts c TGF-B1  a None     100.641  b No a Yes 
26 0.0854 b Collagen degradation b Osteoclasts a None  c A83-01     109.487  a Yes b No 
26 0.1180 b Collagen degradation b Osteoclasts a None  c A83-01     151.282  a Yes b No 
26 0.0988 b Collagen degradation b Osteoclasts a None  c A83-01     126.667  a Yes b No 
26 0.1052 b Collagen degradation b Osteoclasts a None  c A83-01     134.872  a Yes b No 
26 0.1199 b Collagen degradation b Osteoclasts a None  c A83-01     153.718  a Yes b No 
26 0.1104 b Collagen degradation b Osteoclasts a None  c A83-01     141.538  a Yes b No 
26 0.1135 b Collagen degradation b Osteoclasts a None  c A83-01     145.513  a Yes b No 
26 0.0989 b Collagen degradation b Osteoclasts a None  c A83-01     126.795  a Yes b No 
28 0.0920 b Collagen degradation b Osteoclasts d BMP2  a None     117.949  b No a Yes 
28 0.0891 b Collagen degradation b Osteoclasts d BMP2  a None     114.231  b No a Yes 
28 0.0904 b Collagen degradation b Osteoclasts d BMP2  a None     115.897  b No a Yes 
28 0.0998 b Collagen degradation b Osteoclasts d BMP2  a None     127.949  b No a Yes 
28 0.0891 b Collagen degradation b Osteoclasts d BMP2  a None     114.231  b No a Yes 
28 0.0873 b Collagen degradation b Osteoclasts d BMP2  a None     111.923  b No a Yes 
28 0.0882 b Collagen degradation b Osteoclasts d BMP2  a None     113.077  b No a Yes 
28 0.0755 b Collagen degradation b Osteoclasts d BMP2  a None     96.795   b No a Yes 
30 0.1385 b Collagen degradation b Osteoclasts a None  d K02288     177.564  a Yes b No 
30 0.1135 b Collagen degradation b Osteoclasts a None  d K02288     145.513  a Yes b No 
30 0.0760 b Collagen degradation b Osteoclasts a None  d K02288     97.436   a Yes b No 
30 0.1103 b Collagen degradation b Osteoclasts a None  d K02288     141.410  a Yes b No 
30 0.0931 b Collagen degradation b Osteoclasts a None  d K02288     119.359  a Yes b No 
30 0.0829 b Collagen degradation b Osteoclasts a None  d K02288     106.282  a Yes b No 
30 0.1033 b Collagen degradation b Osteoclasts a None  d K02288     132.436  a Yes b No 
30 0.0993 b Collagen degradation b Osteoclasts a None  d K02288     127.308  a Yes b No 
32 0.1002 b Collagen degradation b Osteoclasts a None  e M5939     128.462  a Yes b No 
32 0.0932 b Collagen degradation b Osteoclasts a None  e M5939      119.487  a Yes b No 
32 0.0900 b Collagen degradation b Osteoclasts a None  e M5939      115.385  a Yes b No 
32 0.0921 b Collagen degradation b Osteoclasts a None  e M5939     118.077  a Yes b No 
32 0.0903 b Collagen degradation b Osteoclasts a None  e M5939     115.769  a Yes b No 
32 0.0939 b Collagen degradation b Osteoclasts a None  e M5939     120.385  a Yes b No 
32 0.0882 b Collagen degradation b Osteoclasts a None  e M5939      113.077  a Yes b No 
32 0.0938 b Collagen degradation b Osteoclasts a None  e M5939     120.256  a Yes b No 
34 0.0789 b Collagen degradation b Osteoclasts a None  f Odanacatic 101.154  a Yes b No 
34 0.0985 b Collagen degradation b Osteoclasts a None  f Odanacatic 126.282  a Yes b No 
34 0.0774 b Collagen degradation b Osteoclasts a None  f Odanacatic 99.231                 a Yes b No 
34 0.1426 b Collagen degradation b Osteoclasts a None  f Odanacatic 182.821  a Yes b No 
34 0.1066 b Collagen degradation b Osteoclasts a None  f Odanacatic 136.667  a Yes b No 
34 0.0828 b Collagen degradation b Osteoclasts a None  f Odanacatic 106.154  a Yes b No 
34 0.1116 b Collagen degradation b Osteoclasts a None  f Odanacatic   143.077  a Yes b No 
34 0.0876 b Collagen degradation b Osteoclasts a None  f Odanacatic   112.308  a Yes b No 
36 0.4453 b Collagen degradation b Osteoclasts a None  g Carfilzomib 570.897  a Yes b No 
36 0.1010 b Collagen degradation b Osteoclasts a None  g Carfilzomib 129.487  a Yes b No 
36 0.2937 b Collagen degradation b Osteoclasts a None  g Carfilzomib 376.538  a Yes b No 
36 0.2609 b Collagen degradation b Osteoclasts a None  g Carfilzomib 334.487  a Yes b No 
36 0.4106 b Collagen degradation b Osteoclasts a None  g Carfilzomib 526.410  a Yes b No 
36 0.2046 b Collagen degradation b Osteoclasts a None  g Carfilzomib 262.308  a Yes b No 
 305
Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor Collagen degrad.       Inhibitor?   Bioactive mol.? 
#          (Osteoclasts % crtl)      (YN) (YN) 
 
36 0.4485 b Collagen degradation b Osteoclasts a None  g Carfilzomib        575.000  a Yes b No 
36 0.1516 b Collagen degradation b Osteoclasts a None  g Carfilzomib        194.359  a Yes b No 
38 0.4359 b Collagen degradation b Osteoclasts a None  h Phloretin            558.846  a Yes       b No 
38 0.1617 b Collagen degradation b Osteoclasts a None  h Phloretin            207.308  a Yes b No 
38 0.1944 b Collagen degradation b Osteoclasts a None  h Phloretin            249.231  a Yes b No 
38 0.1981 b Collagen degradation b Osteoclasts a None  h Phloretin            253.974  a Yes b No 
38 0.1909 b Collagen degradation b Osteoclasts a None  h Phloretin            244.744  a Yes b No 
38 0.1361 b Collagen degradation b Osteoclasts a None  h Phloretin             174.487  a Yes b No 
38 0.1804 b Collagen degradation b Osteoclasts a None  h Phloretin             231.282  a Yes b No 
38 0.2072 b Collagen degradation b Osteoclasts a None  h Phloretin             265.641  a Yes b No 
40 0.0572 b Collagen degradation b Osteoclasts a None  i Decitabine            73.333  a Yes b No 
40 0.0676 b Collagen degradation b Osteoclasts a None  i Decitabine            86.667                 a Yes b No 
40 0.0774 b Collagen degradation b Osteoclasts a None  i Decitabine            99.231  a Yes b No 
40 0.0728 b Collagen degradation b Osteoclasts a None  i Decitabine            93.333                       a Yes b No 
40 0.0672 b Collagen degradation b Osteoclasts a None  i Decitabine            86.154                 a Yes b No 
40 0.0693 b Collagen degradation b Osteoclasts a None  i Decitabine            88.846  a Yes b No 
40 0.0715 b Collagen degradation b Osteoclasts a None  i Decitabine             91.667  a Yes b No 
40 0.0721 b Collagen degradation b Osteoclasts a None  i Decitabine             92.436  a Yes b No 
42 0.3200 b Collagen degradation b Osteoclasts a None  j Amiloride               410.256  a Yes b No 
42 0.1913 b Collagen degradation b Osteoclasts a None  j Amiloride               245.256  a Yes b No 
42 0.1851 b Collagen degradation b Osteoclasts a None  j Amiloride               237.308  a Yes b No 
42 0.1625 b Collagen degradation b Osteoclasts a None  j Amiloride               208.333  a Yes b No 
42 0.1831 b Collagen degradation b Osteoclasts a None  j Amiloride               234.744  a Yes b No 
42 0.1818 b Collagen degradation b Osteoclasts a None  j Amiloride               233.077  a Yes b No 
42 0.2135 b Collagen degradation b Osteoclasts a None  j Amiloride               273.718  a Yes b No 
42 0.2583 b Collagen degradation b Osteoclasts a None  j Amiloride                331.154  a Yes b No 
44 0.0750 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin    96.154  a Yes b No 
44 0.0861 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin    110.385  a Yes b No 
44 0.0930 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin    119.231  a Yes b No 
44 0.0850 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin   108.974  a Yes b No 
44 0.0910 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin    116.667  a Yes b No 
44 0.0944 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin    121.026  a Yes b No 
44 0.0738 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin    94.615  a Yes b No 
44 0.0748 b Collagen degradation b Osteoclasts a None  k Osteoprotegerin    95.897  a Yes b No 
46 0.1007 b Collagen degradation b Osteoclasts a None  l Tacrolimus             129.103  a Yes b No 
46 0.1335 b Collagen degradation b Osteoclasts a None  l Tacrolimus             171.154  a Yes b No 
46 0.0894 b Collagen degradation b Osteoclasts a None  l Tacrolimus             114.615  a Yes b No 
46 0.1146 b Collagen degradation b Osteoclasts a None  l Tacrolimus             146.923  a Yes b No 
46 0.0911 b Collagen degradation b Osteoclasts a None  l Tacrolimus             116.795  a Yes b No 
46 0.0973 b Collagen degradation b Osteoclasts a None  l Tacrolimus             124.744  a Yes b No 
46 0.1383 b Collagen degradation b Osteoclasts a None  l Tacrolimus             177.308  a Yes b No 
46 0.1021 b Collagen degradation b Osteoclasts a None  l Tacrolimus             130.897  a Yes b No 
48 0.0862 b Collagen degradation b Osteoclasts a None  m Carbozantnib       110.513  a Yes b No 
48 0.0808 b Collagen degradation b Osteoclasts a None  m Carbozantnib 103.590  a Yes b No 
48 0.0811 b Collagen degradation b Osteoclasts a None  m Carbozantnib       103.974  a Yes b No 
48 0.1240 b Collagen degradation b Osteoclasts a None  m Carbozantnib 158.974  a Yes b No 
48 0.1091 b Collagen degradation b Osteoclasts a None  m Carbozantnib 139.872  a Yes b No 
48 0.0824 b Collagen degradation b Osteoclasts a None  m Carbozantnib 105.641  a Yes b No 
48 0.0989 b Collagen degradation b Osteoclasts a None  m Carbozantnib 126.795  a Yes b No 
48 0.1533 b Collagen degradation b Osteoclasts a None  m Carbozantnib 196.538  a Yes b No 
50 0.0885 b Collagen degradation b Osteoclasts a None  n GM6001 113.462  a Yes b No 
50 0.1046 b Collagen degradation b Osteoclasts a None  n GM6001 134.103  a Yes b No 
50 0.1079 b Collagen degradation b Osteoclasts a None  n GM6001 138.333  a Yes b No 
50 0.1052 b Collagen degradation b Osteoclasts a None  n GM6001 134.872  a Yes b No 
50 0.1243 b Collagen degradation b Osteoclasts a None  n GM6001 159.359  a Yes b No 
50 0.1029 b Collagen degradation b Osteoclasts a None  n GM6001 131.923  a Yes       b No 
50 0.1004 b Collagen degradation b Osteoclasts a None  n GM6001 128.718  a Yes b No 
50 0.1183 b Collagen degradation b Osteoclasts a None  n GM6001 151.667  a Yes b No 
52 0.1614 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 206.923  a Yes b No 
52 0.1070 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 137.179  a Yes b No 
52 0.1112 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 142.564  a Yes b No 
52 0.0898 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 115.128  a Yes b No 
52 0.1109 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 142.179  a Yes b No 
52 0.0850 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 108.974  a Yes b No 
52 0.0893 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 114.487  a Yes b No 
52 0.1383 b Collagen degradation b Osteoclasts a None  o Cathepsin inhibitor 177.308  a Yes b No 
54 0.1024 b Collagen degradation b Osteoclasts a None  p Osteostatin             131.282  a Yes b No 
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54 0.0856 b Collagen degradation b Osteoclasts a None  p Osteostatin            109.744  a Yes b No 
54 0.0999 b Collagen degradation b Osteoclasts a None  p Osteostatin 128.077  a Yes b No 
54 0.0864 b Collagen degradation b Osteoclasts a None  p Osteostatin 110.769                 a Yes b No 
54 0.0881 b Collagen degradation b Osteoclasts a None  p Osteostatin 112.949  a Yes b No 
54 0.0909 b Collagen degradation b Osteoclasts a None  p Osteostatin 116.538  a Yes b No 
54 0.0975 b Collagen degradation b Osteoclasts a None  p Osteostatin 125.000  a Yes b No 




Figure 321.  Raw data used for the statistical analysis of the Proliferation of Osteoblasts 
 
Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor      Proliferation       Inhibitor?   Bioactive mol.? 
#          (Osteoblasts % crtl)      (YN) (YN) 
17 2.9254 c Cell proliferation  a Osteoblasts a None  a None                  265.945  b No b No 
17 0.4844 c Cell proliferation  a Osteoblasts a None  a None                  44.036  b No b No 
17 0.5026 c Cell proliferation  a Osteoblasts a None  a None   45.691  b No b No 
17 0.4854 c Cell proliferation  a Osteoblasts a None  a None   44.127  b No b No 
17 0.4977 c Cell proliferation  a Osteoblasts a None  a None   45.245  b No b No 
17 0.3252 c Cell proliferation  a Osteoblasts a None  a None   29.564  b No b No 
17 3.2928 c Cell proliferation  a Osteoblasts a None  a None   299.345  b No b No 
17 0.2840 c Cell proliferation  a Osteoblasts a None  a None   25.818  b No b No 
19 4.0000 c Cell proliferation  a Osteoblasts b S1P  a None   363.636  b No a Yes 
19 0.6570 c Cell proliferation  a Osteoblasts b S1P  a None   59.727  b No a Yes 
19 0.8687 c Cell proliferation  a Osteoblasts b S1P  a None   78.973  b No a Yes 
19 0.2634 c Cell proliferation  a Osteoblasts b S1P  a None   23.945  b No a Yes 
19 0.5284 c Cell proliferation  a Osteoblasts b S1P  a None   48.036  b No a Yes 
19 0.3210 c Cell proliferation  a Osteoblasts b S1P  a None   29.182  b No a Yes 
19 2.1081 c Cell proliferation  a Osteoblasts b S1P  a None  191.645  b No a Yes 
19 0.3091 c Cell proliferation  a Osteoblasts b S1P  a None   28.100  b No a Yes 
21 4.0000 c Cell proliferation  a Osteoblasts a None  b FTY720   363.636  a Yes b No 
21 1.3799 c Cell proliferation  a Osteoblasts a None  b FTY720   125.445  a Yes b No 
21 1.1467 c Cell proliferation  a Osteoblasts a None  b FTY720   104.245  a Yes b No 
21 1.1350 c Cell proliferation  a Osteoblasts a None  b FTY720   103.182  a Yes b No 
21 1.2397 c Cell proliferation  a Osteoblasts a None  b FTY720   112.700  a Yes b No 
21 0.9708 c Cell proliferation  a Osteoblasts a None  b FTY720   88.255  a Yes b No 
21 1.0392 c Cell proliferation  a Osteoblasts a None  b FTY720   94.473  a Yes b No 
21 1.8205 c Cell proliferation  a Osteoblasts a None  b FTY720   165.500  a Yes b No 
23 2.0993 c Cell proliferation  a Osteoblasts c TGF-B1  a None   190.845  b No a Yes 
23 0.3104 c Cell proliferation  a Osteoblasts c TGF-B1  a None   28.218  b No a Yes 
23 0.3390 c Cell proliferation  a Osteoblasts c TGF-B1  a None   30.818  b No a Yes 
23 0.3534 c Cell proliferation  a Osteoblasts c TGF-B1  a None   32.127  b No a Yes 
23 0.3649 c Cell proliferation  a Osteoblasts c TGF-B1  a None   33.173  b No a Yes 
23 0.3703 c Cell proliferation  a Osteoblasts c TGF-B1  a None   33.664  b No a Yes 
23 0.2603 c Cell proliferation  a Osteoblasts c TGF-B1  a None   23.664  b No a Yes 
23 3.1166 c Cell proliferation  a Osteoblasts c TGF-B1  a None   283.327  b No a Yes 
25 0.8766 c Cell proliferation  a Osteoblasts a None  c A83-01   79.691  a Yes b No 
25 0.2283 c Cell proliferation  a Osteoblasts a None  c A83-01   20.755  a Yes b No 
25 0.5068 c Cell proliferation  a Osteoblasts a None  c A83-01   46.073  a Yes b No 
25 0.3058 c Cell proliferation  a Osteoblasts a None  c A83-01   27.800  a Yes b No 
25 0.3194 c Cell proliferation  a Osteoblasts a None  c A83-01   29.036  a Yes b No 
25 0.3133 c Cell proliferation  a Osteoblasts a None  c A83-01   28.482  a Yes b No 
25 0.2671 c Cell proliferation  a Osteoblasts a None  c A83-01   24.282  a Yes b No 
25 0.4002 c Cell proliferation  a Osteoblasts a None  c A83-01   36.382  a Yes b No 
27 1.5929 c Cell proliferation  a Osteoblasts d BMP2  a None  144.809  b No a Yes 
27 0.2507 c Cell proliferation  a Osteoblasts d BMP2  a None   22.791  b No a Yes 
27 0.5782 c Cell proliferation  a Osteoblasts d BMP2  a None   52.564  b No a Yes 
27 0.5248 c Cell proliferation  a Osteoblasts d BMP2  a None  47.709  b No a Yes 
27 0.5822 c Cell proliferation  a Osteoblasts d BMP2  a None  52.927  b No a Yes 
27 0.3264 c Cell proliferation  a Osteoblasts d BMP2  a None  29.673  b No a Yes 
27 0.2921 c Cell proliferation  a Osteoblasts d BMP2  a None  26.555  b No a Yes 
27 0.4345 c Cell proliferation  a Osteoblasts d BMP2  a None  39.500  b No a Yes 
29 0.3778 c Cell proliferation  a Osteoblasts a None  d K02288  34.345  a Yes b No 
29 0.2461 c Cell proliferation  a Osteoblasts a None  d K02288  22.373  a Yes b No 
29 0.5128 c Cell proliferation  a Osteoblasts a None  d K02288  46.618  a Yes b No 
29 0.3346 c Cell proliferation  a Osteoblasts a None  d K02288  30.418  a Yes b No 
29 0.5740 c Cell proliferation  a Osteoblasts a None  d K02288  52.182  a Yes b No 
29 0.5661 c Cell proliferation  a Osteoblasts a None  d K02288  51.464  a Yes b No 
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Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor        Proliferation       Inhibitor?   Bioactive mol.? 
#          (Osteoblasts % crtl)      (YN) (YN) 
 
29 0.3141 c Cell proliferation  a Osteoblasts a None  d K02288     28.555  a Yes b No 
29 0.4490 c Cell proliferation  a Osteoblasts a None  d K02288     40.818  a Yes b No 
31 0.3804 c Cell proliferation  a Osteoblasts a None  e M5939     34.582  a Yes b No 
31 0.2703 c Cell proliferation  a Osteoblasts a None  e M5939     24.573  a Yes b No 
31 0.2747 c Cell proliferation  a Osteoblasts a None  e M5939     24.973  a Yes b No 
31 0.3218 c Cell proliferation  a Osteoblasts a None  e M5939     29.255  a Yes b No 
31 0.3305 c Cell proliferation  a Osteoblasts a None  e M5939     30.045  a Yes b No 
31 0.3277 c Cell proliferation  a Osteoblasts a None  e M5939     29.791  a Yes b No 
31 0.3114 c Cell proliferation  a Osteoblasts a None  e M5939     28.309  a Yes b No 
31 0.2673 c Cell proliferation  a Osteoblasts a None  e M5939     24.300  a Yes b No 
33 1.8043 c Cell proliferation  a Osteoblasts a None  f Odanacatic    164.027 a Yes b No 
33 0.3266 c Cell proliferation  a Osteoblasts a None  f Odanacatic    29.691  a Yes b No 
33 0.3026 c Cell proliferation  a Osteoblasts a None  f Odanacatic    27.509  a Yes b No 
33 0.4498 c Cell proliferation  a Osteoblasts a None  f Odanacatic    40.891  a Yes b No 
33 0.3467 c Cell proliferation  a Osteoblasts a None  f Odanacatic    31.518  a Yes b No 
33 0.3122 c Cell proliferation  a Osteoblasts a None  f Odanacatic    28.382  a Yes b No 
33 0.5955 c Cell proliferation  a Osteoblasts a None  f Odanacatic    54.136  a Yes b No 
33 0.2962 c Cell proliferation  a Osteoblasts a None  f Odanacatic    26.927  a Yes b No 
35 2.7173 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    247.027 a Yes b No 
35 0.8204 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    74.582  a Yes b No 
35 1.1930 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    108.455 a Yes b No 
35 0.3485 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    31.682  a Yes b No 
35 0.7378 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    67.073  a Yes b No 
35 0.3868 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    35.164  a Yes b No 
35 0.3965 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    36.045  a Yes b No 
35 0.5453 c Cell proliferation  a Osteoblasts a None  g Carfilzomib    49.573  a Yes b No 
37 4.0000 c Cell proliferation  a Osteoblasts a None  h Phloretin    363.636 a Yes b No 
37 4.0000 c Cell proliferation  a Osteoblasts a None  h Phloretin    363.636 a Yes b No 
37 4.0000 c Cell proliferation  a Osteoblasts a None  h Phloretin    363.636 a Yes b No 
37 2.9069 c Cell proliferation  a Osteoblasts a None  h Phloretin    264.264 a Yes b No 
37 3.2260 c Cell proliferation  a Osteoblasts a None  h Phloretin    293.273 a Yes b No 
37 3.0888 c Cell proliferation  a Osteoblasts a None  h Phloretin    280.800 a Yes b No 
37 4.0000 c Cell proliferation  a Osteoblasts a None  h Phloretin    363.636 a Yes b No 
37 4.0000 c Cell proliferation  a Osteoblasts a None  h Phloretin    363.636 a Yes b No 
39 0.7638 c Cell proliferation  a Osteoblasts a None  i Decitabine    69.436  a Yes b No 
39 0.9590 c Cell proliferation  a Osteoblasts a None  i Decitabine    87.182  a Yes b No 
39 1.4722 c Cell proliferation  a Osteoblasts a None  i Decitabine    133.836 a Yes b No 
39 0.5874 c Cell proliferation  a Osteoblasts a None  i Decitabine    53.400  a Yes b No 
39 0.3966 c Cell proliferation  a Osteoblasts a None  i Decitabine    36.055  a Yes b No 
39 0.3676 c Cell proliferation  a Osteoblasts a None  i Decitabine    33.418  a Yes b No 
39 0.2826 c Cell proliferation  a Osteoblasts a None  i Decitabine    25.691  a Yes b No 
39 0.2237 c Cell proliferation  a Osteoblasts a None  i Decitabine    20.336  a Yes b No 
41 1.0345 c Cell proliferation  a Osteoblasts a None  j Amiloride    94.045  a Yes b No 
41 2.7130 c Cell proliferation  a Osteoblasts a None  j Amiloride    246.636 a Yes b No 
41 4.0000 c Cell proliferation  a Osteoblasts a None  j Amiloride    363.636 a Yes b No 
41 4.0000 c Cell proliferation  a Osteoblasts a None  j Amiloride    363.636 a Yes b No 
41 3.4274 c Cell proliferation  a Osteoblasts a None  j Amiloride    311.582 a Yes b No 
41 4.0000 c Cell proliferation  a Osteoblasts a None  j Amiloride    363.636 a Yes b No 
41 2.0700 c Cell proliferation  a Osteoblasts a None  j Amiloride    188.182 a Yes b No 
41 2.0920 c Cell proliferation  a Osteoblasts a None  j Amiloride    190.182 a Yes b No 
43 0.3308 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin       30.073  a Yes b No 
43 0.4408 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin    40.073  a Yes b No 
43 0.2523 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin    22.936  a Yes b No 
43 0.2376 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin    21.600  a Yes b No 
43 0.3951 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin    35.918  a Yes b No 
43 0.2050 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin    18.636  a Yes b No 
43 2.2370 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin    203.364 a Yes b No 
43 2.7526 c Cell proliferation  a Osteoblasts a None  k Osteoprotegerin    250.236 a Yes b No 
45 0.2259 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    20.536  a Yes b No 
45 0.2763 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    25.118  a Yes b No 
45 0.2331 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    21.191  a Yes b No 
45 0.2394 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    21.764  a Yes b No 
45 0.1634 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    14.855  a Yes b No 
45 0.2088 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    18.982  a Yes b No 
45 0.2137 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    19.427  a Yes b No 
45 2.3949 c Cell proliferation  a Osteoblasts a None  l Tacrolimus    217.718 a Yes b No 
47 0.2918 c Cell proliferation  a Osteoblasts a None  m Carbozantnib    26.527  a Yes b No 
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Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor        Proliferation       Inhibitor?   Bioactive mol.? 
#          (Osteoblasts % crtl)      (YN) (YN) 
 
 
47 0.1786 c Cell proliferation  a Osteoblasts a None  m Carbozantnib         16.236  a Yes b No 
47 0.2679 c Cell proliferation  a Osteoblasts a None  m Carbozantnib    24.355  a Yes b No 
47 0.2358 c Cell proliferation  a Osteoblasts a None  m Carbozantnib    21.436  a Yes b No 
47 0.2613 c Cell proliferation  a Osteoblasts a None  m Carbozantnib    23.755  a Yes b No 
47 0.2412 c Cell proliferation  a Osteoblasts a None  m Carbozantnib    21.927  a Yes b No 
47 0.2871 c Cell proliferation  a Osteoblasts a None  m Carbozantnib    26.100  a Yes b No 
47 0.6005 c Cell proliferation  a Osteoblasts a None  m Carbozantnib    54.591  a Yes b No 
49 0.3132 c Cell proliferation  a Osteoblasts a None  n GM6001    28.473  a Yes b No 
49 0.1627 c Cell proliferation  a Osteoblasts a None  n GM6001    14.791  a Yes b No 
49 0.3646 c Cell proliferation  a Osteoblasts a None  n GM6001    33.145  a Yes b No 
49 0.2607 c Cell proliferation  a Osteoblasts a None  n GM6001    23.700  a Yes b No 
49 0.2636 c Cell proliferation  a Osteoblasts a None  n GM6001    23.964  a Yes b No 
49 0.2445 c Cell proliferation  a Osteoblasts a None  n GM6001    22.227  a Yes b No 
49 0.2938 c Cell proliferation  a Osteoblasts a None  n GM6001    26.709  a Yes b No 
49 0.3673 c Cell proliferation  a Osteoblasts a None  n GM6001    33.391  a Yes b No 
51 1.6221 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 147.464  a Yes b No 
51 0.3939 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 35.809  a Yes b No 
51 0.5244 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 47.673  a Yes b No 
51 0.4683 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 42.573  a Yes b No 
51 0.3299 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 29.991  a Yes b No 
51 0.3870 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 35.182  a Yes b No 
51 0.2908 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 26.436  a Yes b No 
51 0.5305 c Cell proliferation  a Osteoblasts a None  o Cathepsin inhibitor 48.227  a Yes b No 
53 1.7182 c Cell proliferation  a Osteoblasts a None  p Osteostatin  156.200  a Yes b No 
53 1.3165 c Cell proliferation  a Osteoblasts a None  p Osteostatin  119.682  a Yes b No 
53 0.8185 c Cell proliferation  a Osteoblasts a None  p Osteostatin  74.409  a Yes b No 
53 0.5344 c Cell proliferation  a Osteoblasts a None  p Osteostatin  48.582  a Yes b No 
53 0.6992 c Cell proliferation  a Osteoblasts a None  p Osteostatin  63.564  a Yes b No 
53 0.4822 c Cell proliferation  a Osteoblasts a None  p Osteostatin  43.836  a Yes b No 
53 0.5137 c Cell proliferation  a Osteoblasts a None  p Osteostatin  46.700  a Yes b No 
53 0.5129 c Cell proliferation  a Osteoblasts a None  p Osteostatin  46.627  a Yes b No 
 
Figure 322.  Raw data used for the statistical analysis of the Proliferation of Osteoclasts 
    
Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor        Proliferation       Inhibitor?   Bioactive mol.? 
#          (Osteoclasts % crtl)      (YN) (YN) 
 
 
18 0.3600 c Cell proliferation  b Osteoclasts a None  a None   87.167  b No b No 
18 0.4120 c Cell proliferation  b Osteoclasts a None  a None   99.758  b No b No 
18 0.4030 c Cell proliferation  b Osteoclasts a None  a None   97.579  b No b No 
18 0.3960 c Cell proliferation  b Osteoclasts a None  a None   95.884  b No b No 
18 0.4950 c Cell proliferation  b Osteoclasts a None  a None  119.855  b No b No 
18 0.4460 c Cell proliferation  b Osteoclasts a None  a None  107.990  b No b No 
18 0.4910 c Cell proliferation  b Osteoclasts a None  a None  118.886  b No b No 
18 0.3010 c Cell proliferation  b Osteoclasts a None  a None  72.881  b No b No 
20 0.4870 c Cell proliferation  b Osteoclasts b S1P  a None  117.918  b No a Yes 
20 0.4870 c Cell proliferation  b Osteoclasts b S1P  a None  117.918  b No a Yes 
20 0.4590 c Cell proliferation  b Osteoclasts b S1P  a None  111.138  b No a Yes 
20 0.4390 c Cell proliferation  b Osteoclasts b S1P  a None  106.295  b No a Yes 
20 0.5090 c Cell proliferation  b Osteoclasts b S1P  a None  123.245  b No a Yes 
20 0.5750 c Cell proliferation  b Osteoclasts b S1P  a None  139.225  b No a Yes 
20 0.6840 c Cell proliferation  b Osteoclasts b S1P  a None  165.617  b No a Yes 
20 0.7130 c Cell proliferation  b Osteoclasts b S1P  a None  172.639  b No a Yes 
22 4.0000 c Cell proliferation  b Osteoclasts a None  b FTY720  968.523  a Yes b No 
22 1.7040 c Cell proliferation  b Osteoclasts a None  b FTY720  412.591  a Yes b No 
22 0.9710 c Cell proliferation  b Osteoclasts a None  b FTY720  235.109  a Yes b No 
22 1.0830 c Cell proliferation  b Osteoclasts a None  b FTY720  262.228  a Yes b No 
22 0.9580 c Cell proliferation  b Osteoclasts a None  b FTY720  231.961  a Yes b No 
22 2.0470 c Cell proliferation  b Osteoclasts a None  b FTY720  495.642  a Yes b No 
22 4.0000 c Cell proliferation  b Osteoclasts a None  b FTY720  968.523  a Yes b No 
22 4.0000 c Cell proliferation  b Osteoclasts a None  b FTY720  968.523  a Yes b No 
24 0.3180 c Cell proliferation  b Osteoclasts c TGF-B1  a None     
 76.998  b No  a Yes 
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Group  Raw (abs) Assay Type Cell Type  Bioactive molecule Inhibitor        Proliferation       Inhibitor?   Bioactive mol.? 
#          (Osteoblasts % crtl)      (YN) (YN) 
 
24 0.2210 c Cell proliferation  b Osteoclasts c TGF-B1  a None  53.511  b No a Yes 
24 0.2160 c Cell proliferation  b Osteoclasts c TGF-B1  a None  52.300  b No a Yes 
24 0.1600 c Cell proliferation  b Osteoclasts c TGF-B1  a None  38.741  b No a Yes 
24 0.1620 c Cell proliferation  b Osteoclasts c TGF-B1  a None  39.225  b No a Yes 
24 0.1970 c Cell proliferation  b Osteoclasts c TGF-B1  a None  47.700  b No a Yes 
24 0.7060 c Cell proliferation  b Osteoclasts c TGF-B1  a None  170.944  b No a Yes 
24 1.0630 c Cell proliferation  b Osteoclasts c TGF-B1  a None  257.385  b No a Yes 
26 0.3070 c Cell proliferation  b Osteoclasts a None  c A83-01  74.334  a Yes b No 
26 0.1510 c Cell proliferation  b Osteoclasts a None  c A83-01  36.562  a Yes b No 
26 0.1340 c Cell proliferation  b Osteoclasts a None  c A83-01  32.446  a Yes b No 
26 0.1560 c Cell proliferation  b Osteoclasts a None  c A83-01  37.772  a Yes b No 
26 0.1500 c Cell proliferation  b Osteoclasts a None  c A83-01  36.320  a Yes b No 
26 0.1430 c Cell proliferation  b Osteoclasts a None  c A83-01  34.625  a Yes b No 
26 0.3550 c Cell proliferation  b Osteoclasts a None  c A83-01  85.956  a Yes b No 
26 0.8730 c Cell proliferation  b Osteoclasts a None  c A83-01  211.380  a Yes b No 
28 0.3070 c Cell proliferation  b Osteoclasts d BMP2  a None  74.334  b No a Yes 
28 0.1630 c Cell proliferation  b Osteoclasts d BMP2  a None  39.467  b No a Yes 
28 0.1760 c Cell proliferation  b Osteoclasts d BMP2  a None  42.615  b No a Yes 
28 0.1560 c Cell proliferation  b Osteoclasts d BMP2  a None  37.772  b No a Yes 
28 0.1690 c Cell proliferation  b Osteoclasts d BMP2  a None  40.920  b No a Yes 
28 0.1720 c Cell proliferation  b Osteoclasts d BMP2  a None  41.646  b No a Yes 
28 0.4310 c Cell proliferation  b Osteoclasts d BMP2  a None  104.358  b No a Yes 
28 1.9710 c Cell proliferation  b Osteoclasts d BMP2  a None  477.240  b No a Yes 
30 0.5570 c Cell proliferation  b Osteoclasts a None  d K02288  134.867  a Yes b No 
30 0.1700 c Cell proliferation  b Osteoclasts a None  d K02288  41.162  a Yes b No 
30 0.1660 c Cell proliferation  b Osteoclasts a None  d K02288  40.194  a Yes b No 
30 0.1550 c Cell proliferation  b Osteoclasts a None  d K02288  37.530  a Yes b No 
30 0.1670 c Cell proliferation  b Osteoclasts a None  d K02288  40.436  a Yes b No 
30 0.1680 c Cell proliferation  b Osteoclasts a None  d K02288  40.678  a Yes b No 
30 0.5530 c Cell proliferation  b Osteoclasts a None  d K02288  133.898  a Yes b No 
30 1.7930 c Cell proliferation  b Osteoclasts a None  d K02288  434.140  a Yes b No 
32 3.3380 c Cell proliferation  b Osteoclasts a None  e M5939  808.232  a Yes b No 
32 0.2070 c Cell proliferation  b Osteoclasts a None  e M5939  50.121  a Yes b No 
32 0.2190 c Cell proliferation  b Osteoclasts a None  e M5939  53.027  a Yes b No 
32 0.1820 c Cell proliferation  b Osteoclasts a None  e M5939  44.068  a Yes b No 
32 0.2070 c Cell proliferation  b Osteoclasts a None  e M5939  50.121  a Yes b No 
32 0.2150 c Cell proliferation  b Osteoclasts a None  e M5939  52.058  a Yes b No 
32 1.0090 c Cell proliferation  b Osteoclasts a None  e M5939  244.310  a Yes b No 
32 2.3250 c Cell proliferation  b Osteoclasts a None  e M5939  562.954  a Yes b No 
34 3.3890 c Cell proliferation  b Osteoclasts a None  f Odanacatic 820.581  a Yes b No 
34 0.2830 c Cell proliferation  b Osteoclasts a None  f Odanacatic 68.523  a Yes b No 
34 0.2540 c Cell proliferation  b Osteoclasts a None  f Odanacatic 61.501  a Yes b No 
34 0.1980 c Cell proliferation  b Osteoclasts a None  f Odanacatic 47.942  a Yes b No 
34 0.1960 c Cell proliferation  b Osteoclasts a None  f Odanacatic 47.458  a Yes b No 
34 0.2280 c Cell proliferation  b Osteoclasts a None  f Odanacatic 55.206  a Yes b No 
34 3.3380 c Cell proliferation  b Osteoclasts a None  f Odanacatic 808.232  a Yes b No 
34 4.0000 c Cell proliferation  b Osteoclasts a None  f Odanacatic 968.523  a Yes b No 
36 4.0000 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 968.523  a Yes b No 
36 0.6610 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 160.048  a Yes b No 
36 0.2480 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 60.048  a Yes b No 
36 0.2240 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 54.237  a Yes b No 
36 0.2090 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 50.605  a Yes b No 
36 0.4320 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 104.600  a Yes b No 
36 3.4680 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 839.709  a Yes b No 
36 3.0880 c Cell proliferation  b Osteoclasts a None  g Carfilzomib 747.700  a Yes b No 
38 1.5650 c Cell proliferation  b Osteoclasts a None  h Phloretin 378.935  a Yes b No 
38 4.0000 c Cell proliferation  b Osteoclasts a None  h Phloretin 968.523  a Yes b No 
38 1.6460 c Cell proliferation  b Osteoclasts a None  h Phloretin 398.547  a Yes b No 
38 1.6960 c Cell proliferation  b Osteoclasts a None  h Phloretin 410.654  a Yes b No 
38 1.6430 c Cell proliferation  b Osteoclasts a None  h Phloretin 397.821  a Yes b No 
38 3.4910 c Cell proliferation  b Osteoclasts a None  h Phloretin 845.278  a Yes b No 
38 1.6500 c Cell proliferation  b Osteoclasts a None  h Phloretin 399.516  a Yes b No 
38 1.1940 c Cell proliferation  b Osteoclasts a None  h Phloretin 289.104  a Yes b No 
40 3.2130 c Cell proliferation  b Osteoclasts a None  i Decitabine 777.966  a Yes b No 
40 4.0000 c Cell proliferation  b Osteoclasts a None  i Decitabine 968.523  a Yes b No 
40 4.0000 c Cell proliferation  b Osteoclasts a None  i Decitabine 968.523  a Yes b No 
40 4.0000 c Cell proliferation  b Osteoclasts a None  i Decitabine 968.523  a Yes b No 
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40 4.0000 c Cell proliferation  b Osteoclasts a None  i Decitabine 968.523  a Yes b No 
40 4.0000 c Cell proliferation  b Osteoclasts a None  i Decitabine 968.523  a Yes b No 
40 3.0790 c Cell proliferation  b Osteoclasts a None  i Decitabine 745.521  a Yes b No 
40 2.7050 c Cell proliferation  b Osteoclasts a None  i Decitabine 654.964  a Yes b No  
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
42 4.0000 c Cell proliferation  b Osteoclasts a None  j Amiloride 968.523  a Yes b No 
44 0.2469 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 59.782  a Yes b No 
44 0.3028 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 73.317  a Yes b No 
44 0.3149 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 76.247  a Yes b No 
44 0.2685 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 65.012  a Yes b No 
44 0.2421 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 58.620  a Yes b No 
44 0.2705 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 65.496  a Yes b No 
44 0.2882 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 69.782  a Yes b No 
44 0.2745 c Cell proliferation  b Osteoclasts a None  k Osteoprotegerin 66.465  a Yes b No 
46 0.2064 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 49.976  a Yes b No 
46 0.2912 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 70.508  a Yes b No 
46 0.2223 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 53.826  a Yes b No 
46 0.2348 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 56.852  a Yes b No 
46 0.1608 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 38.935  a Yes b No 
46 0.2565 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 62.107  a Yes b No 
46 0.2152 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 52.107  a Yes b No 
46 0.2144 c Cell proliferation  b Osteoclasts a None  l Tacrolimus 51.913  a Yes b No 
48 2.7913 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 675.860  a Yes b No 
48 0.8718 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 211.090  a Yes b No 
48 0.6198 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 150.073  a Yes b No 
48 0.6532 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 158.160  a Yes b No 
48 0.6720 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 162.712  a Yes b No 
48 0.8189 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 198.281  a Yes b No 
48 0.7794 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 188.717  a Yes b No 
48 3.4898 c Cell proliferation  b Osteoclasts a None  m Carbozantnib 844.988  a Yes b No 
50 0.2328 c Cell proliferation  b Osteoclasts a None  n GM6001 56.368  a Yes b No 
50 0.2283 c Cell proliferation  b Osteoclasts a None  n GM6001 55.278  a Yes b No 
50 0.3666 c Cell proliferation  b Osteoclasts a None  n GM6001 88.765  a Yes b No 
50 0.2518 c Cell proliferation  b Osteoclasts a None  n GM6001 60.969  a Yes b No 
50 0.2515 c Cell proliferation  b Osteoclasts a None  n GM6001 60.896  a Yes b No 
50 0.2123 c Cell proliferation  b Osteoclasts a None  n GM6001 51.404  a Yes b No 
50 0.2372 c Cell proliferation  b Osteoclasts a None  n GM6001 57.433  a Yes b No 
50 0.3504 c Cell proliferation  b Osteoclasts a None  n GM6001 84.843  a Yes b No 
52 3.4680 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 839.709  a Yes b No 
52 0.8344 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 202.034  a Yes b No 
52 0.8028 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 194.383  a Yes b No 
52 0.8399 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 203.366  a Yes b No 
52 0.6007 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 145.448  a Yes b No 
52 0.6841 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 165.642  a Yes b No 
52 0.7565 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 183.172  a Yes b No 
52 2.4464 c Cell proliferation  b Osteoclasts a None  o Cathepsin inhibitor 592.349  a Yes b No 
54 0.3831 c Cell proliferation  b Osteoclasts a None  p Osteostatin            92.760  a Yes b No 
54 0.1588 c Cell proliferation  b Osteoclasts a None  p Osteostatin  38.450  a Yes b No 
54 0.3272 c Cell proliferation  b Osteoclasts a None  p Osteostatin  79.225  a Yes b No 
54 0.2352 c Cell proliferation  b Osteoclasts a None  p Osteostatin  56.949  a Yes b No 
54 0.3805 c Cell proliferation  b Osteoclasts a None  p Osteostatin  92.131  a Yes b No 
54 0.2583 c Cell proliferation  b Osteoclasts a None  p Osteostatin  62.542  a Yes b No 
54 0.2375 c Cell proliferation  b Osteoclasts a None  p Osteostatin  57.506  a Yes b No 
54 0.3208 c Cell proliferation  b Osteoclasts a None  p Osteostatin  77.676  a Yes b No 
 
